RNA Therapeutics : Pharmaceuticals : UK

<!DOCTYPE html > <html xmlns="http://www.w3.org/1999/xhtml"> <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="SKYPE_TOOLBAR" content="SKYPE_TOOLBAR_PARSER_COMPATIBLE" /><meta name="viewport" content="width=device-width, initial-scale=1" />  <script src="https://cdn-ukwest.onetrust.com/consent/2f42c8dd-6f0d-43ef-8823-35fceb025e84/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="2f42c8dd-6f0d-43ef-8823-35fceb025e84" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>   <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-T3QT4FB');</script>   <script type="text/javascript" src="/_scripts/jquery.min.js"></script> <script type="text/javascript" src="/_scripts/bootstrap.min.js"></script> <script type="text/javascript" src="/_scripts/carouselTicker.min.js"></script> <script type="text/javascript" src="/_scripts/magnific-popup.js"></script> <script type="text/javascript" src="/_scripts/owl.carousel.min.js"></script> <script type="text/javascript" src="/_scripts/jquery.sidr.min.js"></script> <script type="text/javascript" src="/_scripts/jquery.validate.min.js"></script> <script type="text/javascript" src="/_scripts/additional-methods.min.js"></script> <script type="text/javascript" src="/_scripts/imagesloaded.pkgd.min.js"></script> <script type="text/javascript" src="/_scripts/popups/login.js?v=5"></script> <script type="text/javascript" src="/_scripts/popups/signup.js"></script> <script type="text/javascript" src="/_scripts/popups/speak.js"></script> <script type="text/javascript" src="/_scripts/popups/attend.js?v=1"></script> <script type="text/javascript" src="/_scripts/popups/sponsor.js"></script> <script type="text/javascript" src="/_scripts/popups/contact.js"></script> <script type="text/javascript" src="/_scripts/popups/gdpr.js?v=1"></script> <script type="text/javascript" src="/_scripts/popups/misc.js?v=4"></script> <script type="text/javascript" src="/_scripts/popups/downbroch.js?v=1"></script> <script type="text/javascript" src="/_scripts/new/ticker.js"></script> <script type="text/javascript" src="/_scripts/new/sliders.js?v=1"></script>  <script src="https://paypage-cdn.adflex.co.uk/MerchantLibrary/lib.min.js" type="text/javascript"></script> <script type="text/javascript" src="/_scripts/new/checkout.js?v=3"></script> <link href="/_styles/bootstrap.min.css" type="text/css" rel="stylesheet" /><link href="/_styles/jquery.sidr.dark.css" type="text/css" rel="stylesheet" /><link href="/_styles/magnific-popup.css" type="text/css" rel="stylesheet" /><link href="/_styles/owl.carousel.css" type="text/css" rel="stylesheet" /><link href="/_styles/style.css?v=6" type="text/css" rel="stylesheet" /> <script type="text/javascript" src="/_scripts/jquery.easing.js"></script> <script> $(document).ready(function () { $('.open-popup-link').magnificPopup({ type: 'inline', midClick: true // allow opening popup on middle mouse click. Always set it to true if you don't provide alternative source. }); }); </script> <title> RNA Therapeutics : Pharmaceuticals : UK </title> <link rel="canonical" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics" /> <script type="text/javascript"> $(window).scroll(function () { if ($(window).width() > 739) { var scroll = $(window).scrollTop(); if (scroll >= 600) { $(".mid_tab_banner").addClass("fixed2"); $(".mid_tab_sec").addClass("fixed2"); $(".daylist").addClass("fixed2"); } else { $(".mid_tab_banner").removeClass("fixed2"); $(".mid_tab_sec").removeClass("fixed2"); $(".daylist").removeClass("fixed2"); } } else { $(".mid_tab_banner").removeClass("fixed2"); $(".mid_tab_sec").removeClass("fixed2"); $(".daylist").removeClass("fixed2"); } }); function scrollToPosition(targetPos) { if (document.readyState === 'complete') { $('html, body').animate({ scrollTop: targetPos }, 100); } else { $(document).ready(function () { $('html, body').animate({ scrollTop: targetPos }, 100); }); } } $(document).ready(function () { var url = document.location.toString(); if (url.match('#')) { if (url.slice(-1) == "_") { url = url.substr(0, url.length - 1); } $('.nav-tabs a[href=#' + url.split('#')[1] + ']').tab('show'); } $('.nav-tabs a').on('shown.bs.tab', function (e) { window.location.hash = e.target.hash; window.scrollTo(0, 250); }) $('#DDNavigation li a,#btnDownloadCentre').click(function (e) { $('.nav-tabs a[href=' + $(this).attr('href') + ']').tab('show'); }) // Optimalisation: Store the references outside the event handler: var $window = $(window); function checkWidth() { var windowsize = $window.width(); if (url.match('#')) { if (url.split('#')[1] == "eventDetails") { if ( $(window).width() < 480) { window.scrollTo(0, 230); } } } } // Execute on load checkWidth(); // Bind event listener $(window).resize(checkWidth); }); $(window).ready(function () { $("#whySponsor-sponsor-overview-slider").owlCarousel({ items: 4, autoPlay: 3000, //Set AutoPlay to 3 seconds navSpeed: 600, navigation: true, navigationText: ["<", ">"], slideSpeed: 600, loop: true, center: true }); }); /* $(window).load(function () { var gdpr = getCookie("GDPRConsent"); $('#pop-GDPRConsent #GDPRConsent_eventid').text('6065') if (gdpr == "") { $.magnificPopup.open({ items: { src: '#pop-GDPRConsent' }, type: 'inline' }); } }); */ </script> <style> .columntext ul, .latestcontent ul { padding-left: 40px } .columntext li, .latestcontent li { list-style-type: disc; } </style> <meta property="og:title" content="RNA Therapeutics " /><meta property="og:image" content="https://www.smgconferences.com/eventImages/6065_overview.png?width=1036", /><meta property="og:description" content="SAE Media Group is proud to present the 15th Annual RNA Therapeutics Conference on 10 - 11th February 2025." /><meta property="og:url" content="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics" /> <meta name="google-site-verification" content="QUxvzCpDXhln4QcLK-Z5Sp9QR04rGEFbCeiY9Jxm53k" /></head> <body>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-T3QT4FB" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <form method="post" action="./rna-therapeutics" id="aspnetForm" style="height: 0;"> <div class="aspNetHidden"> <input type="hidden" name="ctl00_ToolkitScriptManager1_HiddenField" id="ctl00_ToolkitScriptManager1_HiddenField" value="" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__LASTFOCUS" id="__LASTFOCUS" value="" /> <input type="hidden" name="__VIEWSTATE1" id="__VIEWSTATE1" value="cf0kduxyplqfushdmsjsdbtw_c542168e-de4f-4876-a481-449d14cd4077" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/WebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ window.WebForm_PostBackOptions||document.write('<script type="text/javascript" src="/WebResource.axd?d=oZImrG5UtwhGQ2EFd2xYVfXxME8uqAgUJjvfYmUDuLNuZbTVjhVuiMfiJ9L2oLoXQXiM0aUb0aQ56yEdstw_TqT6ocb3Qsv7nTfVmIYw0FU1&t=638628243619783110"><\/script>');//]]> </script> <script type="text/javascript"> //<![CDATA[ var __cultureInfo = {"name":"en-GB","numberFormat":{"CurrencyDecimalDigits":2,"CurrencyDecimalSeparator":".","IsReadOnly":true,"CurrencyGroupSizes":[3],"NumberGroupSizes":[3],"PercentGroupSizes":[3],"CurrencyGroupSeparator":",","CurrencySymbol":"£","NaNSymbol":"NaN","CurrencyNegativePattern":1,"NumberNegativePattern":1,"PercentPositivePattern":1,"PercentNegativePattern":1,"NegativeInfinitySymbol":"-∞","NegativeSign":"-","NumberDecimalDigits":2,"NumberDecimalSeparator":".","NumberGroupSeparator":",","CurrencyPositivePattern":0,"PositiveInfinitySymbol":"∞","PositiveSign":"+","PercentDecimalDigits":2,"PercentDecimalSeparator":".","PercentGroupSeparator":",","PercentSymbol":"%","PerMilleSymbol":"‰","NativeDigits":["0","1","2","3","4","5","6","7","8","9"],"DigitSubstitution":1},"dateTimeFormat":{"AMDesignator":"AM","Calendar":{"MinSupportedDateTime":"\/Date(-62135596800000)\/","MaxSupportedDateTime":"\/Date(253402300799999)\/","AlgorithmType":1,"CalendarType":1,"Eras":[1],"TwoDigitYearMax":2049,"IsReadOnly":true},"DateSeparator":"/","FirstDayOfWeek":1,"CalendarWeekRule":2,"FullDateTimePattern":"dd MMMM yyyy HH:mm:ss","LongDatePattern":"dd MMMM yyyy","LongTimePattern":"HH:mm:ss","MonthDayPattern":"d MMMM","PMDesignator":"PM","RFC1123Pattern":"ddd, dd MMM yyyy HH\u0027:\u0027mm\u0027:\u0027ss \u0027GMT\u0027","ShortDatePattern":"dd/MM/yyyy","ShortTimePattern":"HH:mm","SortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd\u0027T\u0027HH\u0027:\u0027mm\u0027:\u0027ss","TimeSeparator":":","UniversalSortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd HH\u0027:\u0027mm\u0027:\u0027ss\u0027Z\u0027","YearMonthPattern":"MMMM yyyy","AbbreviatedDayNames":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"ShortestDayNames":["Su","Mo","Tu","We","Th","Fr","Sa"],"DayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"AbbreviatedMonthNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthNames":["January","February","March","April","May","June","July","August","September","October","November","December",""],"IsReadOnly":true,"NativeCalendarName":"Gregorian Calendar","AbbreviatedMonthGenitiveNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthGenitiveNames":["January","February","March","April","May","June","July","August","September","October","November","December",""]},"eras":[1,"A.D.",null,0]};//]]> </script> <script src="/ScriptResource.axd?d=khkmPYFAOU7d2Y-bUMUyQ_brWr3NNRtCccpO71ys36owLUDyjmN-SUgq3YC5ElMr8VL49txeNotB2cH9ZQXaPn5KqrHItjWM70XjglIJfQejPOxqIz8jatHA2SZt1HsO0&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys._Application && Sys.Observer)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=khkmPYFAOU7d2Y-bUMUyQ_brWr3NNRtCccpO71ys36owLUDyjmN-SUgq3YC5ElMr8VL49txeNotB2cH9ZQXaPn5KqrHItjWM70XjglIJfQejPOxqIz8jatHA2SZt1HsO0&t=ffffffffdd783992"><\/script>');//]]> </script> <script src="/ScriptResource.axd?d=kCGEEOkTaMA-ETUe9XtyMaoP2f9Ve0AMk8cO2dpfug3HRbMvbEACk2_P9aOGvBv0-5-ShQ3syc3FIHySKPiyhVmCHTNUTm4cRXeD8-RXStw2-nLeedpIfZaC97ueSZmmzBedTYno2aQ9jgw7f0ltKw2&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.WebForms)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=kCGEEOkTaMA-ETUe9XtyMaoP2f9Ve0AMk8cO2dpfug3HRbMvbEACk2_P9aOGvBv0-5-ShQ3syc3FIHySKPiyhVmCHTNUTm4cRXeD8-RXStw2-nLeedpIfZaC97ueSZmmzBedTYno2aQ9jgw7f0ltKw2&t=ffffffffdd783992"><\/script>');//]]> </script> <script src="/ScriptResource.axd?d=iNKIkAPGpECD5JwIGUPvkUgkJsz8UySman5MYqbNmRiA8Zj6ANbOurMTmC_jp0xY1naCVrdGRAmBloCMQMrCKPqemnV06ELvTJEq_j5MRjlqLfJn9w4rytsd28ggnF2l9H194rxUDDno1aLGK738eZHgOCn139B2utTwMArGzT41&t=ffffffffdd783992" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.Services)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=iNKIkAPGpECD5JwIGUPvkUgkJsz8UySman5MYqbNmRiA8Zj6ANbOurMTmC_jp0xY1naCVrdGRAmBloCMQMrCKPqemnV06ELvTJEq_j5MRjlqLfJn9w4rytsd28ggnF2l9H194rxUDDno1aLGK738eZHgOCn139B2utTwMArGzT41&t=ffffffffdd783992"><\/script>');Sys.Services._AuthenticationService.DefaultWebServicePath = '../../../Authentication_JSON_AppService.axd'; var PageMethods = function() { PageMethods.initializeBase(this); this._timeout = 0; this._userContext = null; this._succeeded = null; this._failed = null; } PageMethods.prototype = { _get_path:function() { var p = this.get_path(); if (p) return p; else return PageMethods._staticInstance.get_path();}, InitSession:function(succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'InitSession',false,{},succeededCallback,failedCallback,userContext); }, GetFirstname:function(succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'GetFirstname',false,{},succeededCallback,failedCallback,userContext); }, GetDialingCode:function(intCountryID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'GetDialingCode',false,{intCountryID:intCountryID},succeededCallback,failedCallback,userContext); }, RegisterAccount:function(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'RegisterAccount',false,{Username:Username,Password:Password,OptOut:OptOut,Title:Title,Surname:Surname,Firstname:Firstname,Organisation:Organisation,JobTitle:JobTitle,Phone:Phone,uid:uid,country:country},succeededCallback,failedCallback,userContext); }, SaveBasket:function(basket,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SaveBasket',false,{basket:basket},succeededCallback,failedCallback,userContext); }, ResetAccountPassword:function(Username,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ResetAccountPassword',false,{Username:Username},succeededCallback,failedCallback,userContext); }, ChangePassword:function(OldPassword,NewPassword,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ChangePassword',false,{OldPassword:OldPassword,NewPassword:NewPassword},succeededCallback,failedCallback,userContext); }, BrochureDownloadSignup:function(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'BrochureDownloadSignup',false,{intEventID:intEventID,strFirstName:strFirstName,strLastName:strLastName,strEmail:strEmail,strCompanyName:strCompanyName,strTelephoneNumber:strTelephoneNumber,blnReceiveInfo:blnReceiveInfo},succeededCallback,failedCallback,userContext); }, BrochureDownload:function(eventId,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'BrochureDownload',false,{eventId:eventId},succeededCallback,failedCallback,userContext); }, ComplementaryContentDownload:function(eventId,complementaryContentId,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ComplementaryContentDownload',false,{eventId:eventId,complementaryContentId:complementaryContentId},succeededCallback,failedCallback,userContext); }, ConferencePresentationDownload:function(intDownloadTypeID,intDownloadID,intEventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ConferencePresentationDownload',false,{intDownloadTypeID:intDownloadTypeID,intDownloadID:intDownloadID,intEventID:intEventID},succeededCallback,failedCallback,userContext); }, ProgrammeNotification:function(EventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ProgrammeNotification',false,{EventID:EventID},succeededCallback,failedCallback,userContext); }, ComplementaryContentDownloadNotification:function(EventID,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ComplementaryContentDownloadNotification',false,{EventID:EventID},succeededCallback,failedCallback,userContext); }, SetPaymentMethod:function(strEncryptedString,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SetPaymentMethod',false,{strEncryptedString:strEncryptedString},succeededCallback,failedCallback,userContext); }, ApplyVoucherCode:function(strWebVoucherCode,strOrderRef,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'ApplyVoucherCode',false,{strWebVoucherCode:strWebVoucherCode,strOrderRef:strOrderRef},succeededCallback,failedCallback,userContext); }, SubmitSpeakerRequest:function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitSpeakerRequest',false,{eventId:eventId,notListedAbove:notListedAbove,howCanWeHelp:howCanWeHelp,organisation:organisation,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,topic:topic,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitAttendRequest:function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitAttendRequest',false,{eventId:eventId,notListedAbove:notListedAbove,howCanWeHelp:howCanWeHelp,organisation:organisation,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitSponsorRequest:function(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitSponsorRequest',false,{eventId:eventId,notListedAbove:notListedAbove,isSponsorLead:isSponsorLead,isSponsorSpeaking:isSponsorSpeaking,isSponsorExhibit:isSponsorExhibit,isSponsorNetworking:isSponsorNetworking,isSponsorCoffeeBreak:isSponsorCoffeeBreak,isSponsorLunch:isSponsorLunch,isSponsorBranding:isSponsorBranding,isSponsorLanyards:isSponsorLanyards,organisation:organisation,jobtitle:jobtitle,website:website,title:title,firstName:firstName,surname:surname,email:email,phone:phone,add:add,sponsorshipGoals:sponsorshipGoals,isReturning:isReturning,heardAboutSmi:heardAboutSmi},succeededCallback,failedCallback,userContext); }, SubmitGDPRConsentRequest:function(eventId,email,giveConsent,name,phone,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitGDPRConsentRequest',false,{eventId:eventId,email:email,giveConsent:giveConsent,name:name,phone:phone},succeededCallback,failedCallback,userContext); }, SubmitGeneralRequest:function(name,jobTitle,org,phone,email,enquiry,enquiryType,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'SubmitGeneralRequest',false,{name:name,jobTitle:jobTitle,org:org,phone:phone,email:email,enquiry:enquiry,enquiryType:enquiryType},succeededCallback,failedCallback,userContext); }, AuthoriseToken:function(strToken,succeededCallback, failedCallback, userContext) { return this._invoke(this._get_path(), 'AuthoriseToken',false,{strToken:strToken},succeededCallback,failedCallback,userContext); }} PageMethods.registerClass('PageMethods',Sys.Net.WebServiceProxy); PageMethods._staticInstance = new PageMethods(); PageMethods.set_path = function(value) { PageMethods._staticInstance.set_path(value); } PageMethods.get_path = function() { return PageMethods._staticInstance.get_path(); } PageMethods.set_timeout = function(value) { PageMethods._staticInstance.set_timeout(value); } PageMethods.get_timeout = function() { return PageMethods._staticInstance.get_timeout(); } PageMethods.set_defaultUserContext = function(value) { PageMethods._staticInstance.set_defaultUserContext(value); } PageMethods.get_defaultUserContext = function() { return PageMethods._staticInstance.get_defaultUserContext(); } PageMethods.set_defaultSucceededCallback = function(value) { PageMethods._staticInstance.set_defaultSucceededCallback(value); } PageMethods.get_defaultSucceededCallback = function() { return PageMethods._staticInstance.get_defaultSucceededCallback(); } PageMethods.set_defaultFailedCallback = function(value) { PageMethods._staticInstance.set_defaultFailedCallback(value); } PageMethods.get_defaultFailedCallback = function() { return PageMethods._staticInstance.get_defaultFailedCallback(); } PageMethods.set_enableJsonp = function(value) { PageMethods._staticInstance.set_enableJsonp(value); } PageMethods.get_enableJsonp = function() { return PageMethods._staticInstance.get_enableJsonp(); } PageMethods.set_jsonpCallbackParameter = function(value) { PageMethods._staticInstance.set_jsonpCallbackParameter(value); } PageMethods.get_jsonpCallbackParameter = function() { return PageMethods._staticInstance.get_jsonpCallbackParameter(); } PageMethods.set_path("rna-therapeutics"); PageMethods.InitSession= function(onSuccess,onFailed,userContext) {PageMethods._staticInstance.InitSession(onSuccess,onFailed,userContext); } PageMethods.GetFirstname= function(onSuccess,onFailed,userContext) {PageMethods._staticInstance.GetFirstname(onSuccess,onFailed,userContext); } PageMethods.GetDialingCode= function(intCountryID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.GetDialingCode(intCountryID,onSuccess,onFailed,userContext); } PageMethods.RegisterAccount= function(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,onSuccess,onFailed,userContext) {PageMethods._staticInstance.RegisterAccount(Username,Password,OptOut,Title,Surname,Firstname,Organisation,JobTitle,Phone,uid,country,onSuccess,onFailed,userContext); } PageMethods.SaveBasket= function(basket,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SaveBasket(basket,onSuccess,onFailed,userContext); } PageMethods.ResetAccountPassword= function(Username,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ResetAccountPassword(Username,onSuccess,onFailed,userContext); } PageMethods.ChangePassword= function(OldPassword,NewPassword,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ChangePassword(OldPassword,NewPassword,onSuccess,onFailed,userContext); } PageMethods.BrochureDownloadSignup= function(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,onSuccess,onFailed,userContext) {PageMethods._staticInstance.BrochureDownloadSignup(intEventID,strFirstName,strLastName,strEmail,strCompanyName,strTelephoneNumber,blnReceiveInfo,onSuccess,onFailed,userContext); } PageMethods.BrochureDownload= function(eventId,onSuccess,onFailed,userContext) {PageMethods._staticInstance.BrochureDownload(eventId,onSuccess,onFailed,userContext); } PageMethods.ComplementaryContentDownload= function(eventId,complementaryContentId,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ComplementaryContentDownload(eventId,complementaryContentId,onSuccess,onFailed,userContext); } PageMethods.ConferencePresentationDownload= function(intDownloadTypeID,intDownloadID,intEventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ConferencePresentationDownload(intDownloadTypeID,intDownloadID,intEventID,onSuccess,onFailed,userContext); } PageMethods.ProgrammeNotification= function(EventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ProgrammeNotification(EventID,onSuccess,onFailed,userContext); } PageMethods.ComplementaryContentDownloadNotification= function(EventID,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ComplementaryContentDownloadNotification(EventID,onSuccess,onFailed,userContext); } PageMethods.SetPaymentMethod= function(strEncryptedString,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SetPaymentMethod(strEncryptedString,onSuccess,onFailed,userContext); } PageMethods.ApplyVoucherCode= function(strWebVoucherCode,strOrderRef,onSuccess,onFailed,userContext) {PageMethods._staticInstance.ApplyVoucherCode(strWebVoucherCode,strOrderRef,onSuccess,onFailed,userContext); } PageMethods.SubmitSpeakerRequest= function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitSpeakerRequest(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,topic,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitAttendRequest= function(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitAttendRequest(eventId,notListedAbove,howCanWeHelp,organisation,website,title,firstName,surname,email,phone,add,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitSponsorRequest= function(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitSponsorRequest(eventId,notListedAbove,isSponsorLead,isSponsorSpeaking,isSponsorExhibit,isSponsorNetworking,isSponsorCoffeeBreak,isSponsorLunch,isSponsorBranding,isSponsorLanyards,organisation,jobtitle,website,title,firstName,surname,email,phone,add,sponsorshipGoals,isReturning,heardAboutSmi,onSuccess,onFailed,userContext); } PageMethods.SubmitGDPRConsentRequest= function(eventId,email,giveConsent,name,phone,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitGDPRConsentRequest(eventId,email,giveConsent,name,phone,onSuccess,onFailed,userContext); } PageMethods.SubmitGeneralRequest= function(name,jobTitle,org,phone,email,enquiry,enquiryType,onSuccess,onFailed,userContext) {PageMethods._staticInstance.SubmitGeneralRequest(name,jobTitle,org,phone,email,enquiry,enquiryType,onSuccess,onFailed,userContext); } PageMethods.AuthoriseToken= function(strToken,onSuccess,onFailed,userContext) {PageMethods._staticInstance.AuthoriseToken(strToken,onSuccess,onFailed,userContext); } var gtc = Sys.Net.WebServiceProxy._generateTypedConstructor; if (typeof(BasketItems) === 'undefined') { var BasketItems=gtc("BasketItems"); BasketItems.registerClass('BasketItems'); } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAASvVXD1oYELeveMr0vHCmYPVi0kMSdTVUTG1voF0fiHcgpO3MFqIPLeyEaVVEMlwUvLjtxrnzfA0pRyMpqEAoQYN3BleO/Qw1FLF2nV9gHb2vx+Sb/n1nfsQ3vvU0HDxJ8=" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$ToolkitScriptManager1', 'aspnetForm', [], [], [], 90, 'ctl00'); //]]> </script> <div class="container-fluid"> <header class="container"> <div class="col-md-3"> <a href="/Default.aspx"><img alt="Home" src="/_images/newsite/logo.png" /></a> </div> <div class="col-md-9"> <div class="participate"> <a href="/about-us/life-at-saemedia/">About Us</a> <a href="/privacy-legals/privacy-policy/">Privacy Policy</a> <a href="/privacy-legals/code-of-conduct/">Conduct</a> <a href="#pop-speak" class="open-popup-link">Speak</a> <a href="#pop-sponsor" class="open-popup-link">Sponsor</a> <a href="#pop-attend" class="open-popup-link">Attend</a> <span id="menu_signup_login" style=""> <a href="#pop-login" class="open-popup-link">Sign up / Login</a><a href="#pop-login" class="open-popup-link linkedin hidden" ></a> </span> <span id="menu_logout" style="display:none"> <a href="javascript:void(0)">Sign out</a> </span> </div> <div class="telmail text-right"> <span> <a href="#pop-contact" class="open-popup-link ">+44 (0)20 7827 6000</a> <a href="#pop-contact" class="open-popup-link">events@saemediagroup.com</a></span> </div> <div class="cart"> <a href="/checkout"><span><img src="/_images/newsite/shopping-cart-16.png" alt="cart" /> Basket Total: £0.00</span></a> </div> </div> </header> </div>  <nav class="navbar navbar-default container-fluid red main-nav"> <div class="container"> <div class="navbar-header"> <button type="button" class="navbar-toggle " id="simple-menu" data-target="#sidr"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div>  <div id="sidr" class="hidden">  <div class="navbar-header pus-menu"> <button type="button" class="navbar-toggle" id="simple-menu2" data-target="#sidr" > <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div> <ul> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_midMenuMain_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> <li><a href="/about-us/life-at-saemedia/">About Us</a></li> <li><a href="/privacy-legals/privacy-policy/">Privacy Policy</a></li> <li><a href="/privacy-legals/code-of-conduct/">Conduct</a></li> <li><a href="#pop-speak" class="open-popup-link">Speak</a></li> <li><a href="#pop-sponsor" class="open-popup-link">Sponsor</a></li> <li><a href="#pop-attend" class="open-popup-link">Attend</a></li> <li><a href="/about-us/help">Help</a></li> </ul> </div> <script> $(document).ready(function () { $('#simple-menu').sidr('open'); $('#simple-menu2').sidr('close'); $('#sidr').removeClass('hidden'); }); </script> <div class="collapse navbar-collapse" id="main-nav"> <ul class="nav navbar-nav"> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_midMenuMain_navbar1_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> </ul> </div> <div class="search" style="display:none;"> <input name="ctl00$midMenuMain$search1$TextBoxSearch" type="text" maxlength="32" onchange="javascript:setTimeout('__doPostBack(\'ctl00$midMenuMain$search1$TextBoxSearch\',\'\')', 0)" onkeypress="if (WebForm_TextBoxKeyHandler(event) == false) return false;" id="ctl00_midMenuMain_search1_TextBoxSearch" /> <a href="#pop-cpd" class="open-popup-link"><img src="/_images/newsite/cpd.png" alt="" class="cpdimg"/></a> </div> </div> </nav> <input type="hidden" name="ctl00$MainContent$eventID" id="ctl00_MainContent_eventID" value="6065" /> <input type="hidden" name="ctl00$MainContent$peventID" id="ctl00_MainContent_peventID" /> <div class="container-fluid darkgrey hidden"> <div class="container carouselTicker"> <ul class="newsticker"> </ul> </div> </div> <div class="image-bg-fluid-height banner" id="intro" style="background: url('https://www.smgconferences.com/_images/eventBanners/6065.jpg') no-repeat 0 0; background-size: cover; "> <div class="earlybird"><p>EARLY BIRD OFFER<span>REGISTER BY<br /> 27 Nov 2024<br /> AND SAVE</span><strong>£100</strong></p></div> <div class="container" style="position:relative; min-height:inherit;"> <div class="dropdown" id="DDNavigation"> <button class="btn btn-default dropdown-toggle" type="button" id="dropdownMenu1" data-toggle="dropdown" aria-expanded="true"> Navigation <span class="caret"></span> </button> <ul class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu1"> <li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_overview">Overview</a></li> <li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_programme">Agenda</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_speakers">Speakers</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_partners">Partners</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_venue">Venue</a></li><li role="presentation"><a role="menuitem" tabindex="-1" href="#tab_downloads">Content</a></li> </ul> </div> <div class="banner-content"> <h1 style="color:#fff;">RNA Therapeutics </h1> <h3 class="pink-header" style="color:#319dd8;"> 10 February - 11 February 2025 <br /> London, United Kingdom<br /> </h3> <p style="color:#fff;">Advancing the next generation of genetic medicine through RNA based therapies</p> <div class="col-xs-12 bottomAlignButtons"> <div class="col-sm-6" style="padding: 0;"> <ul class="button_list"> <li><a href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics/booknow" target="" class="button-blue">Register To Attend</a></li><li><a href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=db&dl=br&p1=6065" target="_blank" class="button-blue downloadBrochure">download brochure</a></li><li><a href="#pop-sponsor" class="open-popup-link button-blue">sponsor or exhibit</a></li><li><a id="btnDownloadCentre" href="#tab_downloads" class="button-blue">content centre</li></a> </ul>  </div>  </div> </div> </div> <div class="banner_corner_ed"><div class="banner_content_ed"><p>EARLY BIRD <span>OFFER</span></p><span> REGISTER BY <br>27 Nov 2024 <br>AND SAVE </span><h2>£100</h2></div></div> </div> <script> $(document).ready(function () { var cdTElem = document.getElementById("countdownText"); var cdDElem = document.getElementById("countdownDate"); var cdDate = new Date("2024-11-28T00:00:00.0000000+00:00").getTime(); var cdText = "Save £100! Early bird ends in: "; SetCountdownTimer(cdTElem, cdText, cdDElem, cdDate); }); function SetCountdownTimer(cdTElem, cdText, cdDElem, cdDate) { cdTElem.innerHTML = cdText; // Update the count down every 1 second var x = setInterval(function () { // Get today's date and time var now = new Date().getTime(); // Find the distance between now and the count down date var distance = cdDate - now; // Time calculations for days, hours, minutes and seconds var days = Math.floor(distance / (1000 * 60 * 60 * 24)); var hours = Math.floor((distance % (1000 * 60 * 60 * 24)) / (1000 * 60 * 60)); var minutes = Math.floor((distance % (1000 * 60 * 60)) / (1000 * 60)); var seconds = Math.floor((distance % (1000 * 60)) / 1000); cdDElem.innerHTML = "| " + days + " Days | " + hours + " Hours | " + minutes + " Minutes | " + seconds + " Seconds "; // If the count down is finished, write some text if (distance < 0) { clearInterval(x); cdTElem.innerHTML = ""; cdDElem.innerHTML = ""; } }, 1000); } </script> <div class="container-fluid" style="background-color:#08478c; "> <div class="container"> <div class="row"> <div class="col-sm-12 text-center" style="padding: 15px 0 15px 0; color: #fff; font-size: 28px;"> <span style="font-weight: 300;" id="countdownText"></span> <span style="font-weight: 600;" id="countdownDate"></span> </div> </div> </div> </div> <div class="mid_tab_sec mid_tab_sec_edit"> <div class="container"> <div class="row"> <div class="col-sm-12"> <div class="mid_tab_Inner"> <div class="mid_top"> <div class="mid_tab_banner /*image-bg-fluid-height banner*/" style="background: url('https://www.smgconferences.com/_images/eventBanners/6065.jpg?height=50&width=1140&mode=crop') no-repeat 0 0;"> <div style="font:700 20px/24px Montserrat; color:#fff; padding-left: 5px; padding-top: 4px;">RNA Therapeutics </div> <div style="font:500 16px/18px Montserrat; color:#fff; padding-left: 5px; ">10 February - 11 February 2025</div> </div> <ul class="nav nav-tabs mid_tab mid_tab_edit" role="tablist">  <li role="presentation"><a href="#tab_overview" aria-controls="tab_new1" role="tab" data-toggle="tab">Overview</a></li> <li id="ctl00_MainContent_liProgramme" role="presentation"><a href="#tab_programme" aria-controls="tab_programme" role="tab" data-toggle="tab">Agenda</a></li> <li id="ctl00_MainContent_liSpeakers" role="presentation"><a href="#tab_speakers" aria-controls="tab_speakers" role="tab" data-toggle="tab">Speakers</a></li> <li id="ctl00_MainContent_liPartners" role="presentation"><a href="#tab_partners" aria-controls="tab_partners" role="tab" data-toggle="tab">Partners</a></li> <li id="ctl00_MainContent_liVenue" role="presentation"><a href="#tab_venue" aria-controls="tab_venue" role="tab" data-toggle="tab">Venue</a></li> <li id="ctl00_MainContent_liDownload" role="presentation"><a href="#tab_downloads" aria-controls="tab_downloads" role="tab" data-toggle="tab">Content</a></li> </ul> <div class="sponcer_event2 sponcer_event_edit" style="float:right"> <ul> <li><a href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=db&dl=br&p1=6065">Download Brochure</a></li> <li><a href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics/booknow" target="" class="actv">Register To Attend</a></li> </ul> </div> </div> </div> </div> </div> </div> </div>  <div class="tab_main"> <div class="container"> <div class="row"> <div class="col-sm-12"> <div class="tab-content"> <div role="tabpanel" class="tab-pane active" id="tab_overview"> <div class="overview"> <div class="row"> <div class="col-md-6"> <div class="overview_pic"> <img id="ctl00_MainContent_ctl02_imgOverviewImage" src="/eventImages/6065_overview.png?width=1036" alt="RNA Therapeutics " /> </div> <div class="col-sm-12" style="margin-top:20px;"> <div class="sharethis "> <div class="share"> <p class="pink-header" style="text-align: left;">follow us</p> <a id="ctl00_MainContent_ctl02_hypLinkedIn" class="addthis_button_linkedin linkedin" href="https://www.linkedin.com/company/saemediagrouppharma/" target="_blank"> <img src="/_images/newsite/In-2C-48px-R.png" border="0" alt="Follow us on LinkedIn" /> </a> <a id="ctl00_MainContent_ctl02_hypTwitter" class="addthis_button_twitter twitter" href="https://x.com/saemgpharma" target="_blank"> <img src="/_images/newsite/x-logo-black.png" border="0" alt="Follow us on X" /> </a> <a href="#pop-ical" class="open-popup-link other"><img src="/_images/newsite/other-red.png" border="0" alt="Add to Calendar" /></a> </div> </div> </div> </div> <div class="col-md-6"> <div style="background-color: #fff;border: none;border-bottom: 1px solid #000;padding: 0;"> <h4 class="panel-title"> <a data-toggle="collapse" data-parent="#accordion" href="#collapseOne" aria-expanded="true" aria-controls="collapseOne">Conference Overview </a> </h4> </div> <div class="panel-body" id="divOverview"> <p>SAE Media Group’s is proud to announce the 15th Annual RNA Therapeutics Conference, taking place on the 10-11 February 2025 in London, UK.</p> <p><br /> The RNA therapeutics industry has grown exponentially in recent years, largely attributed to the advancements in CRISPR RNA-editing technologies, and increased exposure of RNA vaccines following the COVID-19 pandemic. This upward trajectory is expected to continue, with 131 candidate therapies in clinical trials as of January 2024.</p> <p><br /> <strong>Don’t get left behind! </strong>Join us to discuss the latest advancements in RNA therapeutics with leaders from across the life science sector. <br />  </p><p> Expect presentations and discussions addressing novel delivery methods and extra-hepatic delivery solutions, applications of AI for RNA sequence optimisation and case studies of novel modalities progressing through the pipeline including circRNA, siRNA, miRNA, lncRNA and more. Further challenges that will be addressed include the lack of effective assays for in vivo analytical testing, including toxicity and immune-modulation considerations. We will also examine the rapidly changing regulatory landscape, identifying how the industry can adapt to meet changing guidelines and regulations.</p> <p><br /> Don't miss this opportunity to network with the pharma and biotech community of global experts in the UK and Europe; and help shape RNA therapeutic advancements! Our two-day agenda offers you peer-to-peer networking with Directors of key big pharma and biotech’s in the field, CEOs, Senior Scientists, Chief Medical Officers, Senior Vice Presidents and many more.<br />  </p> </div> </div> </div> </div> <div id="speakers"> <h2>FEATURED SPEAKERS</h2> <div id="keynote-slider"> <div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Alessandro Bonetti</a></h3> <div class="speaker-details">Director, AstraZeneca</div> <div class="speaker-profile hidden"><p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224812.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Christalyn Rhodes</a></h3> <div class="speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , Eli Lilly</div> <div class="speaker-profile hidden"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224425.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Ka-Wai Wan" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Ka-Wai Wan</a></h3> <div class="speaker-details">Pharmaceutical Assessor, MHRA</div> <div class="speaker-profile hidden"><p>Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She completed her PhD in protein and gene delivery using nanomedicine at the Welsh School of Pharmacy (Cardiff, UK) and worked as a research academic for over a decade prior to her transition to the MHRA as a pharmaceutical assessor. She now leads on the assessment of nano-based medicinal products, providing scientific and regulatory advice on medicines, particularly on nanomaterials used for both small and macromolecules delivery. This includes nucleic acids delivery using lipid nanoparticles for a wide variety of medical applications.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224786.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Maren von Fritschen" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Maren von Fritschen</a></h3> <div class="speaker-details">Head - Regulatory Policy Europe, Moderna</div> <div class="speaker-profile hidden"><p>Maren von Fritschen is a recognized leader in Regulatory Affairs with 20+ years in Pharma and MedTech. With a PhD in Natural Sciences, she is Head of Regulatory Policy Europe at Moderna, driving regulatory strategies for innovative technologies like mRNA. Maren built the regulatory arm at EUCOPE and was a foundational force behind PharmaLex, later founding AddOn Pharma as CEO. She's chaired DIA's Regional Advisory Council EMEA, contributed to TOPRA, and the STARS project. In the academic realm she is lecturing and mentoring master students at the University of applied sciences, Berlin. Additionally, she has established a comprehensive scientific network across leading Universities in Brazil, focusing on medication in primary health care.</p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224843.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Steve Hood" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Steve Hood</a></h3> <div class="speaker-details">Director, Oligonucleotide ADME Strategy, DMPK, GSK</div> <div class="speaker-profile hidden"><p>Steve Hood received a PhD in Molecular Toxicology from the University of Surrey in 1993 and joined Glaxo Group Research as an Industrial Post doc in the Molecular Biology department in Greenford where he cloned and expressed CYPs in recombinant cell lines. Steve transferred to GlaxoWellcome at Ware in 1995 and became a manager in the new GSK DMPK Molecular Mechanism and Extrapolation Technology team in 2001. In 2010 Steve seconded to Scinovo and co-ordinated the GSK Oligo delivery (GOLD) project and was also Industrial co-lead of the IMI COMPACT consortium that ran from 2012-17 and evaluated delivery mechanisms for oligos and peptides. After a brief return to DMPK in 2015, Steve joined Bioimaging as a senior Scientific Director, responsible for the external imaging collaborations that are members of the Bioimaging Expertise Network (BEN). As part of this network, Steve was also Co-Director of the GSK Centre for Molecular Imaging (COMI) at the University of Illinois at Urbana Champaign, where he worked closely with Professor Stephen Boppart and his team.</p> <p>In addition to his “day job”, Steve has spent most of the last 2 decades working on GSK’s diverse oligo portfolio and has supported projects ranging from inhaled SiRNAs, TLR antagonists, DMD exon skippers (Drisapersen) and ASOs for TTR (Innotersen) and HBV with Ionis (Bepirovirsen). More recently Steve has been involved with the Wave collaboration (Wve-006), the Jade HBV siRNA in licence project and the formation of the Boston Oligo hub.</p> <p>In Jan 2024 Steve rejoined DMPK in and assume the role of Director of Oligo ADME Strategy. Steve will continue to develop the DMPK road map and train and mentor the next generation of DMPK Oligo Project Team Members and SMEs.<br />  </p></div></div></div><div class="keynote-speaker"><a href="#pop-speaker-single" class="open-popup-link" ><div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"><img src="/documentportal/speakerimage/224403.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Urs Langen" class="speaker-image" style="width: 100%; height: auto; " /></div></a><div class="speaker-container"><h3><a href="#pop-speaker-single" style="color: #FFF; text-transform:none; font-size: 20px;" class="open-popup-link speaker-name">Urs Langen</a></h3> <div class="speaker-details">Lab Head, Neuroscience and Rare Diseases, Roche</div> <div class="speaker-profile hidden"><p>Urs Langen studied biochemistry at the University of Tübingen, Germany, before pursuing his PhD in vascular biology in the group of Prof. Ralf Adams at the Max Planck Institute in Münster, Germany. For his postdoctoral studies Urs joined the group of Prof. Chenghua Gu at Harvard Medical School in Boston, USA, where he investigated heterogeneity of the blood brain barrier in various brain areas. After completion of the postdoctoral project Urs joined Roche in Basel, Switzerland, where he has worked for 3 years as a senior scientist on drug delivery to the brain using the Roche Brainshuttle™ technology. Since 2024 Urs heads the Neurovascular Distribution Lab at Roche expanding his work on brain delivery of various drug modalities and leads multiple research projects in the dementia space. During his career Urs published numerous papers in high-impact peer-reviewed scientific journals including Nature and Nature Cell Biology.</p></div></div></div> </div> <script> $(window).ready(function () { $("#keynote-slider").owlCarousel({ //autoPlay: 3000, //Set AutoPlay to 3 seconds slideSpeed: 600, pagination: false, navigation: true, navigationText: ["<", ">"], stopOnHover: true, items: 4, itemsDesktop: [1199, 3], itemsDesktopSmall: [979, 3], center: true, loop: true }); }); </script> <div class="row"> <div class="col-md-12 sponsors marg2"> <div class="buttons"> <a id="hlAll" href="#pop-speakers-all" class="open-popup-link button-white">view all speakers</a> </div> </div> </div> <div id="pop-speakers-all" class="white-popup mfp-hide"> <br> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Alessandro Bonetti</h3> Director, AstraZeneca </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl01_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Christalyn Rhodes</h3> Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , Eli Lilly </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl02_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224812.png?width=200&height=190&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Daniel Tondera</h3> Head of Biology, Pantherna Therapeutics GmbH </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl03_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224200.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Daniel Tondera" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Daniel Tondera is an experienced expert in the field of RNA based therapeutics.<br /> Before joining Pantherna Therapeutics, he was Group Leader at Silence Therapeutics where he was investigating the potential of using miRNAs and mRNA-based gene editing technologies for systemic LNP-mediated therapies. Prior to this he held positions as Group Leader at Cenix Bioscience in Dresden/Germany and as Senior Scientist at CRT in London/UK. <br /> Daniel studied biochemistry at the University of Potsdam/Germany and received his PhD from the University of Potsdam in collaboration with Silence Therapeutics followed by postdoctoral training at the University of Geneva/Switzerland and at the Dana-Farber-Cancer Institute in Boston/MA. <br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Ekkehard Leberer</h3> Consultant, ELBIOCON </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl04_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224195.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Ekkehard Leberer" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Ekkehard serves as CEO at ELBIOCON (www.elbiocon.com) with more than 30 years of experience in biotechnology and pharmaceutical industry. He headed research teams and held managerial positions at the Biotechnology Research Institute of the National Research Council (NRC) of Canada in Montreal and in Big Pharma at Hoechst Marion Roussel, Aventis and Sanofi in Martinsried/Munich and Hoechst/Frankfurt. He was educated in chemistry and molecular biology at the University of Konstanz (Ph.D. and Habilitation in biochemistry) and University of Toronto (PostDoc at the Banting and Best Department of Medical Research). He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.<br /> His scientific and managerial activities included responsibilities in functional genomics, genetic engineering, biological sciences, pre-clinical and clinical development of various therapeutic modalities encompassing small molecule drugs and biopharmaceuticals (peptides, antibodies, oligonucleotides, and mRNAs), drug delivery, portfolio management, external innovation, alliance management and business strategies.<br /> Ekkehard served as a member in Scientific Advisory Boards of several biotechnology companies, and he was the Head of the Supervisory Board of BioM, Munich (www.bio-m.org). He is a member in the life sciences consulting network NewGuide (www.newguide.net).<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Heinrich Haas</h3> CTO, NeoVac </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl05_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224193.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Heinrich Haas" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Jay Sarkar</h3> Researcher , Stanford University </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl06_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224199.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Jay Sarkar" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Sarkar has been in mRNA space for a little over a decade now. His work at Stanford University pioneered the use transiently expressed mRNAs to create an abridged epigenetic reprogramming regimen. This “transient or partial reprogramming” was shown to reset the age of a cell without erasing its identity. From this work, he spun out Turn Bio - the first company around this technology - and this approach has become a lead contender in longevity biotech space. He went on to found his current, new startup - reThink64 - that develops new paradigms for improving delivery of mRNAs and other large molecules.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Juha Monkare</h3> Senior Scientist, Drug Product Development, Johnson & Johnson Innovative Medicine </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl07_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Juha Monkare" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Ka-Wai Wan</h3> Pharmaceutical Assessor, MHRA </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl08_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224425.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Ka-Wai Wan" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She completed her PhD in protein and gene delivery using nanomedicine at the Welsh School of Pharmacy (Cardiff, UK) and worked as a research academic for over a decade prior to her transition to the MHRA as a pharmaceutical assessor. She now leads on the assessment of nano-based medicinal products, providing scientific and regulatory advice on medicines, particularly on nanomaterials used for both small and macromolecules delivery. This includes nucleic acids delivery using lipid nanoparticles for a wide variety of medical applications.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Loic Roux</h3> Co-Founder, OligoTune </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl09_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224489.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Loic Roux" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr. Loïc Roux earned his PhD in Medicinal Chemistry from Aix-Marseille University, focusing on HIV nucleotide pro-drugs. In 2018, he joined Prof. Khvorova's lab at UMass Medical School to work on oligonucleotide stabilization and delivery, and later Prof. Wood's lab at Oxford University for peptide-oligonucleotide conjugates in muscular diseases. After a principal scientist position at PepGen Limited, he helped establish NATA, a UKRI initiative for nucleic acid therapeutics. Moving back to industry as Director of Lead Development at Ochrebio developing RNA therapeutics for liver diseases, he then founded, via the venture studio Deep Science Ventures, OligoTune Limited, a company aiming to revolutionised cancer treatment with RNA technology.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Lucas Bethge</h3> VP Group Lead Oligonucleotide Chemistry, Silence Therapeutics AG </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl10_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224479.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Lucas Bethge" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Lucas Bethge studied chemistry at the Humboldt-University zu Berlin (Germany). After he obtained his Ph.D. in 2011 in Bioorganic Chemistry, he first joined NOXXON Pharma. In 2016 he moved to Silence Therapeutics GmbH, a biotech company in Berlin that develops GalNAc-conjugated siRNA for therapeutic use. Currently, he is Vice-President and leading the Oligonucleotide Chemistry group at Silence Therapeutics. Lucas is an expert for the synthesis, conjugation, and analysis of oligonucleotides with over ten years of experience in industrial research and development at the interface between early research and clinical development.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Maren von Fritschen</h3> Head - Regulatory Policy Europe, Moderna </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl11_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224786.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Maren von Fritschen" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Maren von Fritschen is a recognized leader in Regulatory Affairs with 20+ years in Pharma and MedTech. With a PhD in Natural Sciences, she is Head of Regulatory Policy Europe at Moderna, driving regulatory strategies for innovative technologies like mRNA. Maren built the regulatory arm at EUCOPE and was a foundational force behind PharmaLex, later founding AddOn Pharma as CEO. She's chaired DIA's Regional Advisory Council EMEA, contributed to TOPRA, and the STARS project. In the academic realm she is lecturing and mentoring master students at the University of applied sciences, Berlin. Additionally, she has established a comprehensive scientific network across leading Universities in Brazil, focusing on medication in primary health care.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Margaux Hubert</h3> Senior Scientist - Computational Immunology, mRNA Center of Excellence, Sanofi </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl12_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224818.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Margaux Hubert" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Dr Margaux Hubert is an immunologist by training with a solid foundation in both experimental and computational research. She completed her PhD in immuno-ongology at the Cancer Research Center (CRCL) of Lyon. Through this first experience in research, she developed significant expertise in dendritic cells biology and their pivotal role in initiating immune responses against tumors. After graduating, she acquired complementary skills in bioinformatics and contributed to the identification of new immune biomarkers in tumors during a four-year postdoctoral fellowship in the Cancer Immunology Laboratory of Lyon (LICL). Bridging her knowledge in immunology with computational approaches, she then moved into a researcher position at the Center Léon Bérard anti-cancer hospital (CLB, Lyon, France). In 2024, she joined the mRNA Center of Excellence (CoE) at Sanofi, where she focuses on deciphering the mode of action of mRNA vaccines using both computational approaches and a strong expertise in immunology to analyze high-dimensional exploratory readouts from clinical and preclinical studies.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Mateusz Maciejewski</h3> VP, Head of Data Science, Korro Bio </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl13_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/225036.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Mateusz Maciejewski" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Matt Maciejewski is the VP and Head of Data Science at Korro Bio. With a PhD in computational biophysics from the NIH and University of Edinburgh, he completed postdoctoral fellowships at Cambridge and Novartis NIBR, where he innovated ML methods for cheminformatics. After an 8-year tenure at Pfizer, Matt now leads a team at Korro Bio, developing deep learning models to design chemically modified oligos for precise RNA editing. Overall, his work in machine learning and probabilistic modeling has significantly advanced disease understanding, drug design methods, and patient stratification.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Nagy Habib</h3> Co-Founder and Professor of Surgery, Dawn Therapeutics and Imperial College London </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl14_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224673.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Nagy Habib" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. <br /> He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver <br /> cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the <br /> first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver <br /> failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the <br /> development of saRNA drug (a new class of medicines) which is currently being trialled in patients with <br /> liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov <br /> ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, <br /> ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. <br /> Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and <br /> Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of <br /> EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Russell Hamilton</h3> Associate Principal Scientist, AstraZeneca </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl15_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224815.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Russell Hamilton" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>At AstraZeneca, my research focus is in the field of functional genomics, RNA structure, and epigenetics delving into the intricate mechanisms governing gene expression and regulation. My interdisciplinary approach explores the impact of these processes on disease development and paves the way for innovative therapeutic interventions.</p> <p>Prior to joining AstraZeneca led a research group in the Department of Genetics, University of Cambridge and headed the bioinformatics facility in Centre for Trophoblast Research, University of Cambridge. Previously worked at CEGX (now Biomodal) developing epigenetics sequencing methodologies. <br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Soren Ottosen</h3> VP of Research, Sixfold Bioscience </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl16_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224842.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Soren Ottosen" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Søren Ottosen is an early drug discovery program manager, strategy and project leader with 15 years of experience in identifying nucleic acid-based medicine candidates for clinical development, first at Santaris Pharma as a Senior Research Scientist and then at the Roche Innovation Center Copenhagen. While at Roche, Dr. Ottosen held a number of positions, including Senior Portfolio and Platform Development Leader and Senior Leader. Dr. Ottosen received his Bachelor of Science from the Institute of Molecular Biology at the University of Copenhagen, his Ph.D from the Department of Biochemistry and Molecular Biology at Michigan State University, and did his postdoctoral fellowship in the Department of Microbiology at NYU School of Medicine.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Steve Hood</h3> Director, Oligonucleotide ADME Strategy, DMPK, GSK </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl17_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224843.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Steve Hood" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Steve Hood received a PhD in Molecular Toxicology from the University of Surrey in 1993 and joined Glaxo Group Research as an Industrial Post doc in the Molecular Biology department in Greenford where he cloned and expressed CYPs in recombinant cell lines. Steve transferred to GlaxoWellcome at Ware in 1995 and became a manager in the new GSK DMPK Molecular Mechanism and Extrapolation Technology team in 2001. In 2010 Steve seconded to Scinovo and co-ordinated the GSK Oligo delivery (GOLD) project and was also Industrial co-lead of the IMI COMPACT consortium that ran from 2012-17 and evaluated delivery mechanisms for oligos and peptides. After a brief return to DMPK in 2015, Steve joined Bioimaging as a senior Scientific Director, responsible for the external imaging collaborations that are members of the Bioimaging Expertise Network (BEN). As part of this network, Steve was also Co-Director of the GSK Centre for Molecular Imaging (COMI) at the University of Illinois at Urbana Champaign, where he worked closely with Professor Stephen Boppart and his team.</p> <p>In addition to his “day job”, Steve has spent most of the last 2 decades working on GSK’s diverse oligo portfolio and has supported projects ranging from inhaled SiRNAs, TLR antagonists, DMD exon skippers (Drisapersen) and ASOs for TTR (Innotersen) and HBV with Ionis (Bepirovirsen). More recently Steve has been involved with the Wave collaboration (Wve-006), the Jade HBV siRNA in licence project and the formation of the Boston Oligo hub.</p> <p>In Jan 2024 Steve rejoined DMPK in and assume the role of Director of Oligo ADME Strategy. Steve will continue to develop the DMPK road map and train and mentor the next generation of DMPK Oligo Project Team Members and SMEs.<br />  </p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Steve Pascolo</h3> Principal Investigator, University Hospital of Zurich and University of Zurich </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl18_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224787.png?width=200&height=190&bgcolor=white&scale=canvas" alt="Steve Pascolo" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Trained as an immunologist at the Pasteur Institute (Paris, France), Dr. Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2013, he joined the dermatology department of the University Hospital of Zurich, Switzerland. In 2017, Dr. Pascolo implemented in the University of Zurich an academic mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p> </div> </div> <div class="row" style="border-bottom: 1px solid #a51142; margin:30px 5px;"> <div class="col-sm-8" style="vertical-align: top"> <h3 style="padding-left: 0; margin: 0">Urs Langen</h3> Lab Head, Neuroscience and Rare Diseases, Roche </div> <div class="col-sm-4"> <img id="ctl00_MainContent_ctl04_rptAllSpeakers_ctl19_imgSpeaker" class="img-responsive" src="/documentportal/speakerimage/224403.jpg?width=200&height=190&bgcolor=white&scale=canvas" alt="Urs Langen" align="right" style="margin:5px 0 20px 0;" /> </div> <div class="col-sm-12"> <p>Urs Langen studied biochemistry at the University of Tübingen, Germany, before pursuing his PhD in vascular biology in the group of Prof. Ralf Adams at the Max Planck Institute in Münster, Germany. For his postdoctoral studies Urs joined the group of Prof. Chenghua Gu at Harvard Medical School in Boston, USA, where he investigated heterogeneity of the blood brain barrier in various brain areas. After completion of the postdoctoral project Urs joined Roche in Basel, Switzerland, where he has worked for 3 years as a senior scientist on drug delivery to the brain using the Roche Brainshuttle™ technology. Since 2024 Urs heads the Neurovascular Distribution Lab at Roche expanding his work on brain delivery of various drug modalities and leads multiple research projects in the dementia space. During his career Urs published numerous papers in high-impact peer-reviewed scientific journals including Nature and Nature Cell Biology.</p> </div> </div> <button title="Close (Esc)" type="button" class="mfp-close">×</button> </div> </div> <div id="ctl00_MainContent_divColumntext" class="columntext row" style="margin: 50px 0 50px 0;"> <div class="col-xs-12 col-sm-6"> <p><u><strong>Why you should attend: </strong></u></p> <ul> <li><strong>Engage </strong>in the latest challenges in drug delivery and review the new and emerging alternatives to LNPs, that are broadening opportunities within tissue targeting.</li> <li><strong>Network </strong>with peers and industry experts to share ideas, discover novel solutions to some of the industry’s biggest challenges including biodistribution, controlling immunogenicity and increasing longevity of RNA therapeutic action.</li> <li><strong>Learn</strong> about novel modalities emerging in the space and the manufacturing and analytical strategies advancing development and synthesis of these RNA modalities.</li> <li><strong>Build </strong>your ecosystem within RNA therapeutics to uncover potential collaborators and keep pace with this rapidly-advancing field.</li> </ul> </div> <div class="col-xs-12 col-sm-6"> <p><u><strong> Who should attend:</strong></u></p> <p>Any company striving to deliver optimal RNA therapies to patients in need. <br /> If you or your company are working on or looking to break into any of the following areas, this conference is a must!</p> <ul> <li>RNA therapeutic research and development</li> <li>mRNA vaccines R&D</li> <li>RNA therapeutic delivery methods</li> <li>Analytical method development for oligonucleotide candidate testing</li> <li>RNA manufacturing</li> <li>RNA synthesis</li> <li>Applications of AI within RNA vaccines and therapeutic development <br />  </li> </ul> </div> </div> <div style="margin-top:20px;"> <script> $(window).ready(function () { $("#sponsors-slider").owlCarousel({ items: 0, center: true, autoPlay: 3000, //Set AutoPlay to 3 seconds slideSpeed: 600, loop: true }); }); </script> </div> <div id="ctl00_MainContent_divLatestcontent" class="col-xs-12 col-sm-12 text-center latestcontent" style="padding-bottom:20px;"> <p><strong>Why not partner with us?<br /> By sponsoring, you’ll position your brand for success. Don't miss out on the opportunity to elevate your visibility, credibility, and business prospects—consider sponsorship today!<br /> Please contact Jack Grant at <a href="mailto:Jack.Grant@saemediagroup.com">Jack.Grant@saemediagroup.com</a>or call +44 (0) 20 7827 6113</strong></p> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_programme"> <div class="programme2"> <script> $(document).ready(function () { $('.streamtabs a').click(function (event) { $(this).tab('show'); var target = $(this).attr('href'); $('html, body').animate({ scrollTop: $(target).offset().top }, 800); event.preventDefault(); return false; }); $('.daylist .nav-tabs > li > a, .daylist2 .nav-tabs > li > a').click(function (event) { var target = $(this).attr('href'); $(target).addClass('active').siblings().removeClass('active'); $('.daylist .nav-tabs .nav-link[href="' + target + '"], .daylist2 .nav-tabs .nav-link[href="' + target + '"]').parent().addClass('active').siblings().removeClass('active'); event.preventDefault(); }); }) function setActiveDay(dayNumber) { $('.daylist .nav-tabs li,.daylist2 .nav-tabs li').removeClass('active'); $('.daylist .nav-tabs li a[href*="#day_' + dayNumber + '"],.daylist2.nav - tabs li a[href *= "#day_' + dayNumber + '"]').parent().addClass('active'); } function updateURL(hash) { if (history.pushState) { history.pushState(null, null, hash); } else { location.hash = hash; } } </script> <h2>Conference agenda</h2> <div role="tabpanel" class="tabpanel"> <div class="daylist"> <ul class="nav nav-tabs" role="tablist" style="width:100%" > <li role="presentation" class="active"><a class="nav-link" href="#day_1" aria-controls="day_1" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day one</a></li><li role="presentation" class=""><a class="nav-link" href="#day_2" aria-controls="day_2" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day two</a></li> </ul> </div>  <div id="daycontent" class="tab-content"> <div role="tabpanel" class="tab-pane active" id="day_1"><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">8:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Registration & Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chairs' Opening Remarks</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224812.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christalyn Rhodes, </strong></span><span class="speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , <strong>Eli Lilly</strong></span><div class="hidden speaker-profile"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224193.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Heinrich Haas" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Heinrich Haas, </strong></span><span class="speaker-details">CTO, <strong>NeoVac</strong></span><div class="hidden speaker-profile"><p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">RNA Therapeutics at Eli Lilly – recent strategy and advancements</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224812.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christalyn Rhodes, </strong></span><span class="speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , <strong>Eli Lilly</strong></span><div class="hidden speaker-profile"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div><div class="topic-description"> <li>Explore the potential of novel backbone chemistry and AI guided oligonucleotide design to enhance the safety and potency of RNA based medicine.</li> <li>Investigate the improvements and identification of ligand-based tissue specific targeting strategies for oligonucleotides, analogous to galnac in the liver, but for other tissues such as the lung, brain, or heart.</li> <li>Evaluate novel routes of administration for oligonucleotides, such as transdermal delivery, that can overcome the barriers of stability, bioavailability, and immunogenicity.</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Driving innovation with mRNA platform technologies supported by regulatory provisions</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224786.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Maren von Fritschen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Maren von Fritschen, </strong></span><span class="speaker-details">Head - Regulatory Policy Europe, <strong>Moderna</strong></span><div class="hidden speaker-profile"><p>Maren von Fritschen is a recognized leader in Regulatory Affairs with 20+ years in Pharma and MedTech. With a PhD in Natural Sciences, she is Head of Regulatory Policy Europe at Moderna, driving regulatory strategies for innovative technologies like mRNA. Maren built the regulatory arm at EUCOPE and was a foundational force behind PharmaLex, later founding AddOn Pharma as CEO. She's chaired DIA's Regional Advisory Council EMEA, contributed to TOPRA, and the STARS project. In the academic realm she is lecturing and mentoring master students at the University of applied sciences, Berlin. Additionally, she has established a comprehensive scientific network across leading Universities in Brazil, focusing on medication in primary health care.</p></div><div class="topic-description"> <li>Regulatory understanding of platform technology in the EU and US and the need for global alignment</li> <li>The value of mRNA platform technology for early provision of medicines to patients</li> <li>Platform technology approaches today and in the future</li> <li>The need for scientific platform technology guideline, specific for mRNA medicines</li> <p><br />  </p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Regulatory considerations for RNA-based medicinal products </h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224425.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Ka-Wai Wan" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Ka-Wai Wan, </strong></span><span class="speaker-details">Pharmaceutical Assessor, <strong>MHRA</strong></span><div class="hidden speaker-profile"><p>Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She completed her PhD in protein and gene delivery using nanomedicine at the Welsh School of Pharmacy (Cardiff, UK) and worked as a research academic for over a decade prior to her transition to the MHRA as a pharmaceutical assessor. She now leads on the assessment of nano-based medicinal products, providing scientific and regulatory advice on medicines, particularly on nanomaterials used for both small and macromolecules delivery. This includes nucleic acids delivery using lipid nanoparticles for a wide variety of medical applications.</p></div><div class="topic-description"> <li>Evolving landscape in the regulation of RNA-based medicinal products</li> <li>Key considerations and challenges for product development</li> <li>Support available for industry from the MHRA specifically on innovative medicines</li> <p> </p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Regulatory joint Q&A</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224425.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Ka-Wai Wan" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Ka-Wai Wan, </strong></span><span class="speaker-details">Pharmaceutical Assessor, <strong>MHRA</strong></span><div class="hidden speaker-profile"><p>Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She completed her PhD in protein and gene delivery using nanomedicine at the Welsh School of Pharmacy (Cardiff, UK) and worked as a research academic for over a decade prior to her transition to the MHRA as a pharmaceutical assessor. She now leads on the assessment of nano-based medicinal products, providing scientific and regulatory advice on medicines, particularly on nanomaterials used for both small and macromolecules delivery. This includes nucleic acids delivery using lipid nanoparticles for a wide variety of medical applications.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224786.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Maren von Fritschen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Maren von Fritschen, </strong></span><span class="speaker-details">Head - Regulatory Policy Europe, <strong>Moderna</strong></span><div class="hidden speaker-profile"><p>Maren von Fritschen is a recognized leader in Regulatory Affairs with 20+ years in Pharma and MedTech. With a PhD in Natural Sciences, she is Head of Regulatory Policy Europe at Moderna, driving regulatory strategies for innovative technologies like mRNA. Maren built the regulatory arm at EUCOPE and was a foundational force behind PharmaLex, later founding AddOn Pharma as CEO. She's chaired DIA's Regional Advisory Council EMEA, contributed to TOPRA, and the STARS project. In the academic realm she is lecturing and mentoring master students at the University of applied sciences, Berlin. Additionally, she has established a comprehensive scientific network across leading Universities in Brazil, focusing on medication in primary health care.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Morning break</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Translational Potential of Preclinical Models in Predicting Reactogenicity and Immunogenicity of mRNA Vaccines</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224818.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Margaux Hubert" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Margaux Hubert, </strong></span><span class="speaker-details">Senior Scientist - Computational Immunology, mRNA Center of Excellence, <strong>Sanofi</strong></span><div class="hidden speaker-profile"><p>Dr Margaux Hubert is an immunologist by training with a solid foundation in both experimental and computational research. She completed her PhD in immuno-ongology at the Cancer Research Center (CRCL) of Lyon. Through this first experience in research, she developed significant expertise in dendritic cells biology and their pivotal role in initiating immune responses against tumors. After graduating, she acquired complementary skills in bioinformatics and contributed to the identification of new immune biomarkers in tumors during a four-year postdoctoral fellowship in the Cancer Immunology Laboratory of Lyon (LICL). Bridging her knowledge in immunology with computational approaches, she then moved into a researcher position at the Center Léon Bérard anti-cancer hospital (CLB, Lyon, France). In 2024, she joined the mRNA Center of Excellence (CoE) at Sanofi, where she focuses on deciphering the mode of action of mRNA vaccines using both computational approaches and a strong expertise in immunology to analyze high-dimensional exploratory readouts from clinical and preclinical studies.</p></div><div class="topic-description"> <li>Computational methods for accelerating mRNA vaccine R&D</li> <li>Build an integrated translational model predicting immunogenicity and reactogenicity </li> <li>Ranking mRNA vaccine candidates</li> <li>Preclinical assessment: translatability of models to the clinic</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">12:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Advancing computational approaches to accelerate discovery of novel RNA targets</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224815.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Russell Hamilton" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Russell Hamilton, </strong></span><span class="speaker-details">Associate Principal Scientist, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>At AstraZeneca, my research focus is in the field of functional genomics, RNA structure, and epigenetics delving into the intricate mechanisms governing gene expression and regulation. My interdisciplinary approach explores the impact of these processes on disease development and paves the way for innovative therapeutic interventions.</p> <p>Prior to joining AstraZeneca led a research group in the Department of Genetics, University of Cambridge and headed the bioinformatics facility in Centre for Trophoblast Research, University of Cambridge. Previously worked at CEGX (now Biomodal) developing epigenetics sequencing methodologies. <br />  </p></div><div class="topic-description"> <li>Leveraging computational approaches to target discovery</li> <li>Gaining a deeper understanding of RNA sequence structure, to identify novel sequences for targeting</li> <li>Identifying functional and structured regions of RNA to enable targetability assessment of RNAs with small molecules</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">13:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Networking Lunch</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Sixfold Bioscience: AI-powered RNA delivery</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224842.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Soren Ottosen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Soren Ottosen, </strong></span><span class="speaker-details">VP of Research, <strong>Sixfold Bioscience</strong></span><div class="hidden speaker-profile"><p>Søren Ottosen is an early drug discovery program manager, strategy and project leader with 15 years of experience in identifying nucleic acid-based medicine candidates for clinical development, first at Santaris Pharma as a Senior Research Scientist and then at the Roche Innovation Center Copenhagen. While at Roche, Dr. Ottosen held a number of positions, including Senior Portfolio and Platform Development Leader and Senior Leader. Dr. Ottosen received his Bachelor of Science from the Institute of Molecular Biology at the University of Copenhagen, his Ph.D from the Department of Biochemistry and Molecular Biology at Michigan State University, and did his postdoctoral fellowship in the Department of Microbiology at NYU School of Medicine.</p></div><div class="topic-description"> <li>Nucleic acid-based medicines have demonstrated great potential for novel therapeutic approaches in a few key tissues.</li> <li>This promise is currently limited to diseases manifested in tissues either with natural uptake of nucleic acids, through complex routes of administration, or through a limited number of characterised ligand-conjugates</li> <li>Sixfold is using AI to design effective delivery methods for currently poorly addressed cells and tissues beyond the currently targetable tissue space.<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">ML-based Design of Oligonucleotides that Promote ADAR-Based RNA Editing</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/225036.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Mateusz Maciejewski" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Mateusz Maciejewski, </strong></span><span class="speaker-details">VP, Head of Data Science, <strong>Korro Bio</strong></span><div class="hidden speaker-profile"><p>Matt Maciejewski is the VP and Head of Data Science at Korro Bio. With a PhD in computational biophysics from the NIH and University of Edinburgh, he completed postdoctoral fellowships at Cambridge and Novartis NIBR, where he innovated ML methods for cheminformatics. After an 8-year tenure at Pfizer, Matt now leads a team at Korro Bio, developing deep learning models to design chemically modified oligos for precise RNA editing. Overall, his work in machine learning and probabilistic modeling has significantly advanced disease understanding, drug design methods, and patient stratification.</p></div><div class="topic-description"> <li>We have developed a new few-shot deep learning methodology for oligo design.</li> <li>With this method, we can design oligos that result in strong editing in new targets with 100-200 data points.</li> <li>Our method outcompetes standard methods on numerous counts, including max editing that we can achieve, and consistency in improving editing in an active learning setting. <p> </p> </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Afternoon Break</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Taking an HBV oligo into Ph3 - Reflections from the ADME team</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224843.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Steve Hood" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Steve Hood, </strong></span><span class="speaker-details">Director, Oligonucleotide ADME Strategy, DMPK, <strong>GSK</strong></span><div class="hidden speaker-profile"><p>Steve Hood received a PhD in Molecular Toxicology from the University of Surrey in 1993 and joined Glaxo Group Research as an Industrial Post doc in the Molecular Biology department in Greenford where he cloned and expressed CYPs in recombinant cell lines. Steve transferred to GlaxoWellcome at Ware in 1995 and became a manager in the new GSK DMPK Molecular Mechanism and Extrapolation Technology team in 2001. In 2010 Steve seconded to Scinovo and co-ordinated the GSK Oligo delivery (GOLD) project and was also Industrial co-lead of the IMI COMPACT consortium that ran from 2012-17 and evaluated delivery mechanisms for oligos and peptides. After a brief return to DMPK in 2015, Steve joined Bioimaging as a senior Scientific Director, responsible for the external imaging collaborations that are members of the Bioimaging Expertise Network (BEN). As part of this network, Steve was also Co-Director of the GSK Centre for Molecular Imaging (COMI) at the University of Illinois at Urbana Champaign, where he worked closely with Professor Stephen Boppart and his team.</p> <p>In addition to his “day job”, Steve has spent most of the last 2 decades working on GSK’s diverse oligo portfolio and has supported projects ranging from inhaled SiRNAs, TLR antagonists, DMD exon skippers (Drisapersen) and ASOs for TTR (Innotersen) and HBV with Ionis (Bepirovirsen). More recently Steve has been involved with the Wave collaboration (Wve-006), the Jade HBV siRNA in licence project and the formation of the Boston Oligo hub.</p> <p>In Jan 2024 Steve rejoined DMPK in and assume the role of Director of Oligo ADME Strategy. Steve will continue to develop the DMPK road map and train and mentor the next generation of DMPK Oligo Project Team Members and SMEs.<br />  </p></div><div class="topic-description"> <li>Understanding the plasma and tissue pharmacokinetics of a GalNAc targeted ASO and its major (unconjugated) metabolite.</li> <li>A recognition that GalNAc targeting has a modest effect on the total liver burden of ASO but a profound effect on the cellular distribution within the liver.</li> <li>A review of the Drug-Drug Interaction (DDI) risks with Bepirovirsen, to enable Phase 3 clinical trials.</li> <li>Understanding why the non-targeted Bepirovirsen outperformed the GalNAc conjugated GSK3389404 in the clinic and subsequent development of novel cellular biodistribution and imaging methodologies.<br /> <br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">16:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Characterization of siRNA product-related impurities by HILIC</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224479.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Lucas Bethge" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Lucas Bethge, </strong></span><span class="speaker-details">VP Group Lead Oligonucleotide Chemistry, <strong>Silence Therapeutics AG</strong></span><div class="hidden speaker-profile"><p>Lucas Bethge studied chemistry at the Humboldt-University zu Berlin (Germany). After he obtained his Ph.D. in 2011 in Bioorganic Chemistry, he first joined NOXXON Pharma. In 2016 he moved to Silence Therapeutics GmbH, a biotech company in Berlin that develops GalNAc-conjugated siRNA for therapeutic use. Currently, he is Vice-President and leading the Oligonucleotide Chemistry group at Silence Therapeutics. Lucas is an expert for the synthesis, conjugation, and analysis of oligonucleotides with over ten years of experience in industrial research and development at the interface between early research and clinical development.</p></div><div class="topic-description"> <li>The presentation will showcase the selection and synthesis of relevant siRNA product-related impurities.</li> <li>Development of a chromatographic method for separation of impurities through HILIC will be demonstrated.</li> <li>The ability of HILIC to complement other separation modes (AEX, IP-RP) will be discussed.<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">17:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chairs' Closing Remarks and Close of Day One</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224812.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christalyn Rhodes, </strong></span><span class="speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , <strong>Eli Lilly</strong></span><div class="hidden speaker-profile"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224193.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Heinrich Haas" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Heinrich Haas, </strong></span><span class="speaker-details">CTO, <strong>NeoVac</strong></span><div class="hidden speaker-profile"><p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p></div></div></div></div></div><div role="tabpanel" class="tab-pane" id="day_2"><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">8:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Registration & Coffee</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chairs' Opening Remarks</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224193.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Heinrich Haas" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Heinrich Haas, </strong></span><span class="speaker-details">CTO, <strong>NeoVac</strong></span><div class="hidden speaker-profile"><p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224812.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christalyn Rhodes, </strong></span><span class="speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , <strong>Eli Lilly</strong></span><div class="hidden speaker-profile"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Assessing the current RNA Therapeutics Landscape </h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224193.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Heinrich Haas" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Heinrich Haas, </strong></span><span class="speaker-details">CTO, <strong>NeoVac</strong></span><div class="hidden speaker-profile"><p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p></div><div class="topic-description"> <li>Overview of current challenges within the RNA therapeutics and vaccines space</li> <li>Recent advancements, breakthroughs and novel technologies</li> <li>Future perspectives – where is the field headed</li> <p> </p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">9:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Beyond Antibody Delivery – Expanding the Cargo Space of the Brainshuttle™ to ASOs</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224403.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Urs Langen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Urs Langen, </strong></span><span class="speaker-details">Lab Head, Neuroscience and Rare Diseases, <strong>Roche</strong></span><div class="hidden speaker-profile"><p>Urs Langen studied biochemistry at the University of Tübingen, Germany, before pursuing his PhD in vascular biology in the group of Prof. Ralf Adams at the Max Planck Institute in Münster, Germany. For his postdoctoral studies Urs joined the group of Prof. Chenghua Gu at Harvard Medical School in Boston, USA, where he investigated heterogeneity of the blood brain barrier in various brain areas. After completion of the postdoctoral project Urs joined Roche in Basel, Switzerland, where he has worked for 3 years as a senior scientist on drug delivery to the brain using the Roche Brainshuttle™ technology. Since 2024 Urs heads the Neurovascular Distribution Lab at Roche expanding his work on brain delivery of various drug modalities and leads multiple research projects in the dementia space. During his career Urs published numerous papers in high-impact peer-reviewed scientific journals including Nature and Nature Cell Biology.</p></div><div class="topic-description"> <li>Design and generation of Brainshuttle-ASO conjugates for CNS delivery of ASOs after I.V.administration</li> <li>Broad biodistribution of Brainshuttle-ASOs in the brain</li> <li>Robust target knockdown of target in brain after intravenous Brainshuttle-ASO administration<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">10:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Morning Break</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Evaluation and selection of RNA lipid nanoparticle mixing systems: an industry perspective (provisional)</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Juha Monkare" /></a></div></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Juha Monkare, </strong></span><span class="speaker-details">Senior Scientist, Drug Product Development, <strong>Johnson & Johnson Innovative Medicine</strong></span><div class="topic-description"> <li>Overview of methods to prepare RNA-LNPs</li> <li>Review of available mixing systems and their key differences</li> <li>Selection criteria and process to choose the mixing system matching the user requirements<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">11:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Drug Routers: A Novel Paradigm for RNA Drug Delivery</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224199.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Jay Sarkar" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Jay Sarkar, </strong></span><span class="speaker-details">Researcher , <strong>Stanford University</strong></span><div class="hidden speaker-profile"><p>Dr. Sarkar has been in mRNA space for a little over a decade now. His work at Stanford University pioneered the use transiently expressed mRNAs to create an abridged epigenetic reprogramming regimen. This “transient or partial reprogramming” was shown to reset the age of a cell without erasing its identity. From this work, he spun out Turn Bio - the first company around this technology - and this approach has become a lead contender in longevity biotech space. He went on to found his current, new startup - reThink64 - that develops new paradigms for improving delivery of mRNAs and other large molecules.</p></div><div class="topic-description"> <li>Comparison of current carrier-based approaches vs a new networking strategy for delivery</li> <li>Demonstration and topological characterization of network formation</li> <li>Showcase of the variety of applications and unique production features</li> <li>Delivery profiling in novel tissues in animal models.<strong><br /> </strong></li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">12:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Networking Lunch</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">13:20</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Exploring novel indications for LNP-mediated extra-hepatic RNA therapeutic delivery </h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224200.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Daniel Tondera" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Daniel Tondera, </strong></span><span class="speaker-details">Head of Biology, <strong>Pantherna Therapeutics GmbH </strong></span><div class="hidden speaker-profile"><p>Daniel Tondera is an experienced expert in the field of RNA based therapeutics.<br /> Before joining Pantherna Therapeutics, he was Group Leader at Silence Therapeutics where he was investigating the potential of using miRNAs and mRNA-based gene editing technologies for systemic LNP-mediated therapies. Prior to this he held positions as Group Leader at Cenix Bioscience in Dresden/Germany and as Senior Scientist at CRT in London/UK. <br /> Daniel studied biochemistry at the University of Potsdam/Germany and received his PhD from the University of Potsdam in collaboration with Silence Therapeutics followed by postdoctoral training at the University of Geneva/Switzerland and at the Dana-Farber-Cancer Institute in Boston/MA. <br />  </p></div><div class="topic-description"> <li>Exploration of novel LNPs for extra-hepatic targeting</li> <li>Working backwards – identifying cell types that can be successfully entered, before establishing the specific disease indications this could impact</li> <li>Case study examples of exploratory delivery of mRNA to novel tissues for prevention of edema</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:00</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Reviewing the advances in novel RNA modalities</h3></div></div></div><div class="keynote-speaker clearfix"><div class="col-xs-2" style="float: left; padding-left:5px"></div><div class="col-xs-10" style="overflow:auto;"><div class="topic-description"> <li>How do we see the RNA therapeutic landscape evolving in years to come? Will mRNA and RNAi continue to dominate the market or will new players enter the game? </li> <li>Reviewing the latest RNA modalities breaking into the field: saRNA, circRNA, siRNA, lncRNA , RNA editing – which modality has the most potential in treating disease </li> <li>Looking forward – which modalities overcome extra-hepatic delivery and drive advancements in RNA therapeutics</li> </div></div></p></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224195.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Ekkehard Leberer" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Ekkehard Leberer, </strong></span><span class="speaker-details">Consultant, <strong>ELBIOCON</strong></span><div class="hidden speaker-profile"><p>Ekkehard serves as CEO at ELBIOCON (www.elbiocon.com) with more than 30 years of experience in biotechnology and pharmaceutical industry. He headed research teams and held managerial positions at the Biotechnology Research Institute of the National Research Council (NRC) of Canada in Montreal and in Big Pharma at Hoechst Marion Roussel, Aventis and Sanofi in Martinsried/Munich and Hoechst/Frankfurt. He was educated in chemistry and molecular biology at the University of Konstanz (Ph.D. and Habilitation in biochemistry) and University of Toronto (PostDoc at the Banting and Best Department of Medical Research). He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.<br /> His scientific and managerial activities included responsibilities in functional genomics, genetic engineering, biological sciences, pre-clinical and clinical development of various therapeutic modalities encompassing small molecule drugs and biopharmaceuticals (peptides, antibodies, oligonucleotides, and mRNAs), drug delivery, portfolio management, external innovation, alliance management and business strategies.<br /> Ekkehard served as a member in Scientific Advisory Boards of several biotechnology companies, and he was the Head of the Supervisory Board of BioM, Munich (www.bio-m.org). He is a member in the life sciences consulting network NewGuide (www.newguide.net).<br />  </p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224489.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Loic Roux" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Loic Roux, </strong></span><span class="speaker-details">Co-Founder, <strong>OligoTune</strong></span><div class="hidden speaker-profile"><p>Dr. Loïc Roux earned his PhD in Medicinal Chemistry from Aix-Marseille University, focusing on HIV nucleotide pro-drugs. In 2018, he joined Prof. Khvorova's lab at UMass Medical School to work on oligonucleotide stabilization and delivery, and later Prof. Wood's lab at Oxford University for peptide-oligonucleotide conjugates in muscular diseases. After a principal scientist position at PepGen Limited, he helped establish NATA, a UKRI initiative for nucleic acid therapeutics. Moving back to industry as Director of Lead Development at Ochrebio developing RNA therapeutics for liver diseases, he then founded, via the venture studio Deep Science Ventures, OligoTune Limited, a company aiming to revolutionised cancer treatment with RNA technology.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224842.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Soren Ottosen" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Soren Ottosen, </strong></span><span class="speaker-details">VP of Research, <strong>Sixfold Bioscience</strong></span><div class="hidden speaker-profile"><p>Søren Ottosen is an early drug discovery program manager, strategy and project leader with 15 years of experience in identifying nucleic acid-based medicine candidates for clinical development, first at Santaris Pharma as a Senior Research Scientist and then at the Roche Innovation Center Copenhagen. While at Roche, Dr. Ottosen held a number of positions, including Senior Portfolio and Platform Development Leader and Senior Leader. Dr. Ottosen received his Bachelor of Science from the Institute of Molecular Biology at the University of Copenhagen, his Ph.D from the Department of Biochemistry and Molecular Biology at Michigan State University, and did his postdoctoral fellowship in the Department of Microbiology at NYU School of Medicine.</p></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">14:40</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Afternoon Break</h3></div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">LncRNA – strategy and recent breakthroughs at AZ</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/silhouette_M.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Alessandro Bonetti, </strong></span><span class="speaker-details">Director, <strong>AstraZeneca</strong></span><div class="hidden speaker-profile"><p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p></div><div class="topic-description"> <li>Overview of the non-coding field</li> <li>Non-coding elements as novel pharmacological targets</li> <li>Developing a technological pipeline for identification and validation of non-coding pharmacological targets</li> <li>RNA therapeutics targeting non-coding elements<br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">15:50</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">mRNA vaccines – the latest advancements in fighting infectious disease and cancer</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224787.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Steve Pascolo" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Steve Pascolo, </strong></span><span class="speaker-details">Principal Investigator, <strong>University Hospital of Zurich and University of Zurich</strong></span><div class="hidden speaker-profile"><p>Trained as an immunologist at the Pasteur Institute (Paris, France), Dr. Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2013, he joined the dermatology department of the University Hospital of Zurich, Switzerland. In 2017, Dr. Pascolo implemented in the University of Zurich an academic mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p></div><div class="topic-description"> <li>Clinical developments from mRNA vaccine candidates targeting infectious diseases and cancer</li> <li>New synthetic mRNA formats</li> <li>Assessing the mRNA landscape - what challenges remain and what potential does this modality have to impact patients worldwide<br /> <br />  </li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">16:30</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">RNA activation and bio-distribution</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224673.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Nagy Habib" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Nagy Habib, </strong></span><span class="speaker-details">Co-Founder and Professor of Surgery, <strong>Dawn Therapeutics and Imperial College London</strong></span><div class="hidden speaker-profile"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. <br /> He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver <br /> cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the <br /> first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver <br /> failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the <br /> development of saRNA drug (a new class of medicines) which is currently being trialled in patients with <br /> liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov <br /> ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, <br /> ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. <br /> Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and <br /> Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of <br /> EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London</p></div><div class="topic-description"> <li>RNA activation using small activating RNA [saRNA] can be useful in the treatment of myeloid-rich resistant cancer as well as in rare genetic diseases</li> <li>TfR aptamer can lead to brain biodistribution of nucleic acids as well as lipid nano-particles</li> </div></div></div></div><div class="event agenda-box row" style="background-color:#fff;"><div class="row no-gutter" style="background-color:#08478c;"><div class="col-xs-12"><div class="col-xs-2" style="padding-left:0"><div class="col-xs-12 col-sm-6" style="padding-left:0"><img src="/_images/newsite/clock.png" alt="clock" ></div><div class="col-xs-12 col-sm-6" style="padding-left:5px"><h3 style="color:#fff;">17:10</h3></div></div> <div class="col-xs-10 text-right"><h3 style="color:#fff;">Chairs' Closing Remarks and Close of Day Two</h3></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224193.jpg?width=180&height=180&bgcolor=white&scale=canvas" alt="Heinrich Haas" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Heinrich Haas, </strong></span><span class="speaker-details">CTO, <strong>NeoVac</strong></span><div class="hidden speaker-profile"><p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p></div></div></div><div class="keynote-speaker"><div class="col-xs-2" ><div class="row" style="background-color:#fff;"><div class="col-xs-12 speaker-image-circle"><a href="#pop-speaker-single" class="open-popup-link"><img class="speaker-image img-responsive" src="/documentportal/speakerimage/224812.png?width=180&height=180&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" /></a></a></div><div class="col-xs-12 speaker-bio text-center"><a href="#pop-speaker-single" class="open-popup-link">View Bio</a></div><br/></div></div><div class="col-xs-10" style="overflow:auto;"><p><span class="speaker-name"><strong>Christalyn Rhodes, </strong></span><span class="speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , <strong>Eli Lilly</strong></span><div class="hidden speaker-profile"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div></div></div></div></div> </div>  <div class="daylist2"> <ul class="nav nav-tabs" role="tablist" > <li role="presentation" class="active"><a class="nav-link" href="#day_1" aria-controls="day_1" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day one</a></li><li role="presentation" class=""><a class="nav-link" href="#day_2" aria-controls="day_2" role="tab" data-toggle="tab" onclick="scrollToPosition(600);">Day two</a></li> </ul> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_speakers"> <div id="speaker-grid"> <div id="pop-speakers-all" class="container-fluid" style="margin-bottom: 20px;"> <br> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl01_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Alessandro Bonetti" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Alessandro Bonetti</a></div> <div style="margin-top:5px"">Director</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">AstraZeneca</div> <div class="hidden speaker-details">Director, AstraZeneca</div> <div class="hidden speaker-profile"><p>Dr. Alessandro Bonetti obtained his Master degree in Medical Biotechnologies at the University of Naples in 2001 and moved to Helsinki for his PhD studies where he investigated the genetic prediposition to multiple sclerosis in Nordic populations. He then moved to RIKEN Yokohama to study the biological role of long non-coding. During that time he developed numerous technologies to identify the functional relevance of non-coding transcripts in physiological and pathological conditions. Subsequently he joined AstraZeneca to lead the transcriptomic studies in the Oligonucleotide platform. In October 2022 he was appointed Principal Scientist to lead the non-coding initiative in AZ.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl02_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224812.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Christalyn Rhodes" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Christalyn Rhodes</a></div> <div style="margin-top:5px"">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations </div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Eli Lilly</div> <div class="hidden speaker-details">Associate Vice President - Genetic Medicine - External Partnerships and Academic Collaborations , Eli Lilly</div> <div class="hidden speaker-profile"><p>Christalyn Rhodes, PhD is currently the Associate Vice President Genetic Medicine, External Partnering and Collaborations for Eli Lilly and Company  here she identifies opportunities, manages deals, and innovates nuanced strategies and collaboration agreements to develop genetic medicine strategically aligned with Eli Lilly core therapeutic areas. Additionally, Christalyn serves as the Expert-In-Residence for Harvard Innovation Labs, on the board of University of Massachusetts Medical School’s Bridge Fund, as well as an advisor to the Nucleate organization where she has supported the launch and advancement of several startups ranging from idea stage and brainstorming to securing funding. Previously, Christalyn worked as a Venture Capital Associate for Flagship Pioneering where she co-founded a biotechnological platform company to create novel therapeutics in the space of personalized genomic medicine. Dr. Rhodes received a Ph.D. in Biological Sciences from Harvard University and a BA from the University of North Texas.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl03_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224200.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Daniel Tondera" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Daniel Tondera</a></div> <div style="margin-top:5px"">Head of Biology</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Pantherna Therapeutics GmbH </div> <div class="hidden speaker-details">Head of Biology, Pantherna Therapeutics GmbH </div> <div class="hidden speaker-profile"><p>Daniel Tondera is an experienced expert in the field of RNA based therapeutics.<br /> Before joining Pantherna Therapeutics, he was Group Leader at Silence Therapeutics where he was investigating the potential of using miRNAs and mRNA-based gene editing technologies for systemic LNP-mediated therapies. Prior to this he held positions as Group Leader at Cenix Bioscience in Dresden/Germany and as Senior Scientist at CRT in London/UK. <br /> Daniel studied biochemistry at the University of Potsdam/Germany and received his PhD from the University of Potsdam in collaboration with Silence Therapeutics followed by postdoctoral training at the University of Geneva/Switzerland and at the Dana-Farber-Cancer Institute in Boston/MA. <br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl04_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224195.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Ekkehard Leberer" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Ekkehard Leberer</a></div> <div style="margin-top:5px"">Consultant</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">ELBIOCON</div> <div class="hidden speaker-details">Consultant, ELBIOCON</div> <div class="hidden speaker-profile"><p>Ekkehard serves as CEO at ELBIOCON (www.elbiocon.com) with more than 30 years of experience in biotechnology and pharmaceutical industry. He headed research teams and held managerial positions at the Biotechnology Research Institute of the National Research Council (NRC) of Canada in Montreal and in Big Pharma at Hoechst Marion Roussel, Aventis and Sanofi in Martinsried/Munich and Hoechst/Frankfurt. He was educated in chemistry and molecular biology at the University of Konstanz (Ph.D. and Habilitation in biochemistry) and University of Toronto (PostDoc at the Banting and Best Department of Medical Research). He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.<br /> His scientific and managerial activities included responsibilities in functional genomics, genetic engineering, biological sciences, pre-clinical and clinical development of various therapeutic modalities encompassing small molecule drugs and biopharmaceuticals (peptides, antibodies, oligonucleotides, and mRNAs), drug delivery, portfolio management, external innovation, alliance management and business strategies.<br /> Ekkehard served as a member in Scientific Advisory Boards of several biotechnology companies, and he was the Head of the Supervisory Board of BioM, Munich (www.bio-m.org). He is a member in the life sciences consulting network NewGuide (www.newguide.net).<br />  </p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl05_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224193.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Heinrich Haas" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Heinrich Haas</a></div> <div style="margin-top:5px"">CTO</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">NeoVac</div> <div class="hidden speaker-details">CTO, NeoVac</div> <div class="hidden speaker-profile"><p>Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl06_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224199.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Jay Sarkar" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Jay Sarkar</a></div> <div style="margin-top:5px"">Researcher </div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Stanford University</div> <div class="hidden speaker-details">Researcher , Stanford University</div> <div class="hidden speaker-profile"><p>Dr. Sarkar has been in mRNA space for a little over a decade now. His work at Stanford University pioneered the use transiently expressed mRNAs to create an abridged epigenetic reprogramming regimen. This “transient or partial reprogramming” was shown to reset the age of a cell without erasing its identity. From this work, he spun out Turn Bio - the first company around this technology - and this approach has become a lead contender in longevity biotech space. He went on to found his current, new startup - reThink64 - that develops new paradigms for improving delivery of mRNAs and other large molecules.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl07_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/silhouette_M.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Juha Monkare" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Juha Monkare</a></div> <div style="margin-top:5px"">Senior Scientist, Drug Product Development</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Johnson & Johnson Innovative Medicine</div> <div class="hidden speaker-details">Senior Scientist, Drug Product Development, Johnson & Johnson Innovative Medicine</div> <div class="hidden speaker-profile"></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl08_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224425.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Ka-Wai Wan" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Ka-Wai Wan</a></div> <div style="margin-top:5px"">Pharmaceutical Assessor</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">MHRA</div> <div class="hidden speaker-details">Pharmaceutical Assessor, MHRA</div> <div class="hidden speaker-profile"><p>Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She completed her PhD in protein and gene delivery using nanomedicine at the Welsh School of Pharmacy (Cardiff, UK) and worked as a research academic for over a decade prior to her transition to the MHRA as a pharmaceutical assessor. She now leads on the assessment of nano-based medicinal products, providing scientific and regulatory advice on medicines, particularly on nanomaterials used for both small and macromolecules delivery. This includes nucleic acids delivery using lipid nanoparticles for a wide variety of medical applications.</p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl09_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224489.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Loic Roux" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Loic Roux</a></div> <div style="margin-top:5px"">Co-Founder</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">OligoTune</div> <div class="hidden speaker-details">Co-Founder, OligoTune</div> <div class="hidden speaker-profile"><p>Dr. Loïc Roux earned his PhD in Medicinal Chemistry from Aix-Marseille University, focusing on HIV nucleotide pro-drugs. In 2018, he joined Prof. Khvorova's lab at UMass Medical School to work on oligonucleotide stabilization and delivery, and later Prof. Wood's lab at Oxford University for peptide-oligonucleotide conjugates in muscular diseases. After a principal scientist position at PepGen Limited, he helped establish NATA, a UKRI initiative for nucleic acid therapeutics. Moving back to industry as Director of Lead Development at Ochrebio developing RNA therapeutics for liver diseases, he then founded, via the venture studio Deep Science Ventures, OligoTune Limited, a company aiming to revolutionised cancer treatment with RNA technology.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl10_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224479.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Lucas Bethge" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Lucas Bethge</a></div> <div style="margin-top:5px"">VP Group Lead Oligonucleotide Chemistry</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Silence Therapeutics AG</div> <div class="hidden speaker-details">VP Group Lead Oligonucleotide Chemistry, Silence Therapeutics AG</div> <div class="hidden speaker-profile"><p>Lucas Bethge studied chemistry at the Humboldt-University zu Berlin (Germany). After he obtained his Ph.D. in 2011 in Bioorganic Chemistry, he first joined NOXXON Pharma. In 2016 he moved to Silence Therapeutics GmbH, a biotech company in Berlin that develops GalNAc-conjugated siRNA for therapeutic use. Currently, he is Vice-President and leading the Oligonucleotide Chemistry group at Silence Therapeutics. Lucas is an expert for the synthesis, conjugation, and analysis of oligonucleotides with over ten years of experience in industrial research and development at the interface between early research and clinical development.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl11_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224786.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Maren von Fritschen" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Maren von Fritschen</a></div> <div style="margin-top:5px"">Head - Regulatory Policy Europe</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Moderna</div> <div class="hidden speaker-details">Head - Regulatory Policy Europe, Moderna</div> <div class="hidden speaker-profile"><p>Maren von Fritschen is a recognized leader in Regulatory Affairs with 20+ years in Pharma and MedTech. With a PhD in Natural Sciences, she is Head of Regulatory Policy Europe at Moderna, driving regulatory strategies for innovative technologies like mRNA. Maren built the regulatory arm at EUCOPE and was a foundational force behind PharmaLex, later founding AddOn Pharma as CEO. She's chaired DIA's Regional Advisory Council EMEA, contributed to TOPRA, and the STARS project. In the academic realm she is lecturing and mentoring master students at the University of applied sciences, Berlin. Additionally, she has established a comprehensive scientific network across leading Universities in Brazil, focusing on medication in primary health care.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl12_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224818.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Margaux Hubert" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Margaux Hubert</a></div> <div style="margin-top:5px"">Senior Scientist - Computational Immunology, mRNA Center of Excellence</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Sanofi</div> <div class="hidden speaker-details">Senior Scientist - Computational Immunology, mRNA Center of Excellence, Sanofi</div> <div class="hidden speaker-profile"><p>Dr Margaux Hubert is an immunologist by training with a solid foundation in both experimental and computational research. She completed her PhD in immuno-ongology at the Cancer Research Center (CRCL) of Lyon. Through this first experience in research, she developed significant expertise in dendritic cells biology and their pivotal role in initiating immune responses against tumors. After graduating, she acquired complementary skills in bioinformatics and contributed to the identification of new immune biomarkers in tumors during a four-year postdoctoral fellowship in the Cancer Immunology Laboratory of Lyon (LICL). Bridging her knowledge in immunology with computational approaches, she then moved into a researcher position at the Center Léon Bérard anti-cancer hospital (CLB, Lyon, France). In 2024, she joined the mRNA Center of Excellence (CoE) at Sanofi, where she focuses on deciphering the mode of action of mRNA vaccines using both computational approaches and a strong expertise in immunology to analyze high-dimensional exploratory readouts from clinical and preclinical studies.</p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl13_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/225036.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Mateusz Maciejewski" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Mateusz Maciejewski</a></div> <div style="margin-top:5px"">VP, Head of Data Science</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Korro Bio</div> <div class="hidden speaker-details">VP, Head of Data Science, Korro Bio</div> <div class="hidden speaker-profile"><p>Matt Maciejewski is the VP and Head of Data Science at Korro Bio. With a PhD in computational biophysics from the NIH and University of Edinburgh, he completed postdoctoral fellowships at Cambridge and Novartis NIBR, where he innovated ML methods for cheminformatics. After an 8-year tenure at Pfizer, Matt now leads a team at Korro Bio, developing deep learning models to design chemically modified oligos for precise RNA editing. Overall, his work in machine learning and probabilistic modeling has significantly advanced disease understanding, drug design methods, and patient stratification.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl14_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224673.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Nagy Habib" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Nagy Habib</a></div> <div style="margin-top:5px"">Co-Founder and Professor of Surgery</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Dawn Therapeutics and Imperial College London</div> <div class="hidden speaker-details">Co-Founder and Professor of Surgery, Dawn Therapeutics and Imperial College London</div> <div class="hidden speaker-profile"><p>For over three decades Nagy has been at the forefront of clinical research and clinical practise in cancer. <br /> He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver <br /> cancer, as well as the use of plasmid gene therapy in hydrodynamic gene therapy delivery. He was the <br /> first in Europe to perform a clinical trial with the use of adult CD34+ stem cells in patients with liver <br /> failure and stroke.<br /> Nagy is a founder and was the Head of R&D of Mina therapeutics whilst at Mina he was driving the <br /> development of saRNA drug (a new class of medicines) which is currently being trialled in patients with <br /> liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, Clinical Trials.gov <br /> ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, <br /> ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.<br /> He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. <br /> Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide delivery and <br /> Dawn Therapeutics specialising in gene therapy. Previously Nagy was founder and Chairman of <br /> EMcision Limited (acquired by Boston Scientific Inc in 2018).<br /> Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl15_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224815.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Russell Hamilton" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Russell Hamilton</a></div> <div style="margin-top:5px"">Associate Principal Scientist</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">AstraZeneca</div> <div class="hidden speaker-details">Associate Principal Scientist, AstraZeneca</div> <div class="hidden speaker-profile"><p>At AstraZeneca, my research focus is in the field of functional genomics, RNA structure, and epigenetics delving into the intricate mechanisms governing gene expression and regulation. My interdisciplinary approach explores the impact of these processes on disease development and paves the way for innovative therapeutic interventions.</p> <p>Prior to joining AstraZeneca led a research group in the Department of Genetics, University of Cambridge and headed the bioinformatics facility in Centre for Trophoblast Research, University of Cambridge. Previously worked at CEGX (now Biomodal) developing epigenetics sequencing methodologies. <br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl16_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224842.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Soren Ottosen" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Soren Ottosen</a></div> <div style="margin-top:5px"">VP of Research</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Sixfold Bioscience</div> <div class="hidden speaker-details">VP of Research, Sixfold Bioscience</div> <div class="hidden speaker-profile"><p>Søren Ottosen is an early drug discovery program manager, strategy and project leader with 15 years of experience in identifying nucleic acid-based medicine candidates for clinical development, first at Santaris Pharma as a Senior Research Scientist and then at the Roche Innovation Center Copenhagen. While at Roche, Dr. Ottosen held a number of positions, including Senior Portfolio and Platform Development Leader and Senior Leader. Dr. Ottosen received his Bachelor of Science from the Institute of Molecular Biology at the University of Copenhagen, his Ph.D from the Department of Biochemistry and Molecular Biology at Michigan State University, and did his postdoctoral fellowship in the Department of Microbiology at NYU School of Medicine.</p></div> </div> </div> </div> </div> <div class="row"> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl17_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224843.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Steve Hood" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Steve Hood</a></div> <div style="margin-top:5px"">Director, Oligonucleotide ADME Strategy, DMPK</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">GSK</div> <div class="hidden speaker-details">Director, Oligonucleotide ADME Strategy, DMPK, GSK</div> <div class="hidden speaker-profile"><p>Steve Hood received a PhD in Molecular Toxicology from the University of Surrey in 1993 and joined Glaxo Group Research as an Industrial Post doc in the Molecular Biology department in Greenford where he cloned and expressed CYPs in recombinant cell lines. Steve transferred to GlaxoWellcome at Ware in 1995 and became a manager in the new GSK DMPK Molecular Mechanism and Extrapolation Technology team in 2001. In 2010 Steve seconded to Scinovo and co-ordinated the GSK Oligo delivery (GOLD) project and was also Industrial co-lead of the IMI COMPACT consortium that ran from 2012-17 and evaluated delivery mechanisms for oligos and peptides. After a brief return to DMPK in 2015, Steve joined Bioimaging as a senior Scientific Director, responsible for the external imaging collaborations that are members of the Bioimaging Expertise Network (BEN). As part of this network, Steve was also Co-Director of the GSK Centre for Molecular Imaging (COMI) at the University of Illinois at Urbana Champaign, where he worked closely with Professor Stephen Boppart and his team.</p> <p>In addition to his “day job”, Steve has spent most of the last 2 decades working on GSK’s diverse oligo portfolio and has supported projects ranging from inhaled SiRNAs, TLR antagonists, DMD exon skippers (Drisapersen) and ASOs for TTR (Innotersen) and HBV with Ionis (Bepirovirsen). More recently Steve has been involved with the Wave collaboration (Wve-006), the Jade HBV siRNA in licence project and the formation of the Boston Oligo hub.</p> <p>In Jan 2024 Steve rejoined DMPK in and assume the role of Director of Oligo ADME Strategy. Steve will continue to develop the DMPK road map and train and mentor the next generation of DMPK Oligo Project Team Members and SMEs.<br />  </p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl18_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224787.png?width=250&height=250&bgcolor=white&scale=canvas" alt="Steve Pascolo" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Steve Pascolo</a></div> <div style="margin-top:5px"">Principal Investigator</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">University Hospital of Zurich and University of Zurich</div> <div class="hidden speaker-details">Principal Investigator, University Hospital of Zurich and University of Zurich</div> <div class="hidden speaker-profile"><p>Trained as an immunologist at the Pasteur Institute (Paris, France), Dr. Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2013, he joined the dermatology department of the University Hospital of Zurich, Switzerland. In 2017, Dr. Pascolo implemented in the University of Zurich an academic mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.</p></div> </div> </div> </div> <div class="col-xs-12 col-sm-6 col-lg-3 speaker-grid"> <div class="col-sm-12" style="margin-top:20px"> <a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details"> <div style="position: relative; width: 250px; height: 250px; overflow: hidden; border-radius: 50%; border:2px solid black; margin-left:auto; margin-right:auto; margin-bottom: 20px;"> <img id="ctl00_MainContent_ctl05_rptAllSpeakers_ctl19_imgSpeaker" class="img-responsive speaker-image" src="/documentportal/speakerimage/224403.jpg?width=250&height=250&bgcolor=white&scale=canvas" alt="Urs Langen" align="right" style="width:100%; height:auto; " /> </div> </a> </div> <div class="col-sm-12"> <div class="" style="text-align:center; min-height:125px;"> <div class="speaker-name" style="margin-top:20px; font-weight:700;"><a href="#pop-speaker-single" class="open-popup-link" title="Speaker Details">Urs Langen</a></div> <div style="margin-top:5px"">Lab Head, Neuroscience and Rare Diseases</div> <div style="margin-top:5px; font-weight:700; font-color: #000;">Roche</div> <div class="hidden speaker-details">Lab Head, Neuroscience and Rare Diseases, Roche</div> <div class="hidden speaker-profile"><p>Urs Langen studied biochemistry at the University of Tübingen, Germany, before pursuing his PhD in vascular biology in the group of Prof. Ralf Adams at the Max Planck Institute in Münster, Germany. For his postdoctoral studies Urs joined the group of Prof. Chenghua Gu at Harvard Medical School in Boston, USA, where he investigated heterogeneity of the blood brain barrier in various brain areas. After completion of the postdoctoral project Urs joined Roche in Basel, Switzerland, where he has worked for 3 years as a senior scientist on drug delivery to the brain using the Roche Brainshuttle™ technology. Since 2024 Urs heads the Neurovascular Distribution Lab at Roche expanding his work on brain delivery of various drug modalities and leads multiple research projects in the dementia space. During his career Urs published numerous papers in high-impact peer-reviewed scientific journals including Nature and Nature Cell Biology.</p></div> </div> </div> </div> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_sponsors"> <div class="sponsor_new sponsor-elem"> </div> <div class="other_sponser_sec"> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_partners"> <div class="sponsor_new sponsor-elem"> </div> <div class="sponsor_new sponsor-elem"> </div> <div class="other_sponser_sec"> <div class="container-fluid"> <div class="col-md-12" style=""> <h3>Official Media Partner</h3> <ul style="float: none; text-align: center;"> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl07_rptSponsors_ctl01_imgSponsor" class="sponsor-image" src="/_media/partners/2920.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl01_lblName" class="hidden sponsor-name">ONdrugDelivery Magazine</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl01_lblType" class="hidden sponsor-type">Official Media Partner</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl01_lblLink" class="hidden sponsor-link">http://ondrugdelivery.com</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl01_lblProfile" class="hidden sponsor-profile">ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl07_rptSponsors_ctl02_imgSponsor" class="sponsor-image" src="/_media/partners/4110.png?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl02_lblName" class="hidden sponsor-name">Pharma Journalist </span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl02_lblType" class="hidden sponsor-type">Official Media Partner</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl02_lblLink" class="hidden sponsor-link">http://www.pharmajournalist.com</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl02_lblProfile" class="hidden sponsor-profile">Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl07_rptSponsors_ctl03_imgSponsor" class="sponsor-image" src="/_media/partners/2411.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl03_lblName" class="hidden sponsor-name">pharmaphorum</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl03_lblType" class="hidden sponsor-type">Official Media Partner</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl03_lblLink" class="hidden sponsor-link">http://www.pharmaphorum.com</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl03_lblProfile" class="hidden sponsor-profile">pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com</span> </div> </li> <li style="float:none; width:210px; margin:25px;text-align:center; display:inline-block;"> <div class="sponsor-elem"> <a href="#pop-sponsor-single" class="open-popup-link "><img id="ctl00_MainContent_ctl07_rptSponsors_ctl04_imgSponsor" class="sponsor-image" src="/_media/partners/4284.jpg?width=200" /></a><br /> <a href="#pop-sponsor-single" class="open-popup-link view_det">View details</a> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl04_lblName" class="hidden sponsor-name">The Medicine Maker</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl04_lblType" class="hidden sponsor-type">Official Media Partner</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl04_lblLink" class="hidden sponsor-link">https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo</span> <span id="ctl00_MainContent_ctl07_rptSponsors_ctl04_lblProfile" class="hidden sponsor-profile"> The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo </span> </div> </li> </ul> </div> </div> <div class="clearfix"></div> <div class="buttons buttons_ed" style="margin-bottom: 40px;"> <a id="ctl00_MainContent_ctl07_rptSponsors_ctl05_lnkPopup" class="button-white open-popup-link" href="#pop-official-media-partner">view all Official Media Partners</a> <a href="#pop-sponsor" class="button-white open-popup-link">Sponsor the conference</a> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_associatedevents"> <div class="associate_event_sec"> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_venue"> <div class="venue_sec"> <h2 class="font_weght">VENUE</h2> <h2 class="font_weght2">Hilton London Kensington</h2> <p>179-199 Holland Park Avenue, London, United Kingdom</p> <div class="row"> <div class="col-sm-6"> <div class="venue_left"> <a href="#"><img src="/documentPortal/venueImages/319.jpg" alt="" /></a> </div> </div> <div class="col-sm-6"> <div class="venue_map"> <iframe src="https://www.google.com/maps/d/u/0/embed?mid=zDxkJou5X4vI.k2pc1IMkZJhg"></iframe> </div> </div> </div> <div class="row"> <div class="col-sm-12"> <div class="venue_details"> <p><p>At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.</p> <div style="margin: 0cm"> <div style="margin: 0cm"> </div> <div style="margin: 0cm">Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”</div> </div></p> <div style="text-align:left"> <strong>A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.</strong> </div> <a href="/documentPortal/hotelBookingForms/6065.pdf?v=1">HOTEL BOOKING FORM</a> </div> </div> </div> </div> </div> <div role="tabpanel" class="tab-pane" id="tab_downloads"> <div id="downloads"> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl00_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5540"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl00_imgDownload" src="/documentportal/ComplementaryContent/5540.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Speaker Interview - Mateusz Maciejewski</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl00_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5540">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl01_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5536"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl01_imgDownload" src="/documentportal/ComplementaryContent/5536.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Speaker Interview - Steve Pascolo (Principal Investigator, University Hospital of Zurich and University of Zurich)</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl01_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5536">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl02_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5535"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl02_imgDownload" src="/documentportal/ComplementaryContent/5535.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Speaker Interview - Ka-Wai Wan (Pharmaceutical Assessor, MHRA)</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl02_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5535">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl03_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5492"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl03_imgDownload" src="/documentportal/ComplementaryContent/5492.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Video Speaker Interview - Dr. Søren Ottosen</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl03_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5492">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl04_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5384"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl04_imgDownload" src="/documentportal/ComplementaryContent/5384.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>2024 Co-Chairs Letter</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl04_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5384">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl05_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5383"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl05_imgDownload" src="/documentportal/ComplementaryContent/5383.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Presentation - Astrazeneca</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl05_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5383">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl06_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5382"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl06_imgDownload" src="/documentportal/ComplementaryContent/5382.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Presentation - Jonhson & Jonhson</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl06_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5382">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl07_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5381"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl07_imgDownload" src="/documentportal/ComplementaryContent/5381.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Presentation - Eli Lily</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl07_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5381">Download</a> </div> </div> </div> <div class="col-md-4"> <div class="download_list2"> <div class="download_list2_pic"> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl08_hypDownload1" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5369"><img id="ctl00_MainContent_ctl12_rptDownloads_ctl08_imgDownload" src="/documentportal/ComplementaryContent/5369.png?width=320&height=320&canvas=white" /></a> </div> <div class="download_list2_txt"> <h4>Past Attendee List</h4> <a id="ctl00_MainContent_ctl12_rptDownloads_ctl08_hypDownload2" href="https://www.smgconferences.com/pharmaceuticals/uk/conference/rna-therapeutics?o=login&dpb=1&dl=cc&p1=6065&p2=5369">Download</a> </div> </div> </div>  </div> </div> </div> </div> </div> </div> </div> <div> <div class="container"> <div class="row"> <div class="col-sm-12"> </div> </div> </div> </div> <div id="pop-official-media-partner" class="white-popup mfp-hide"> <h3 style="padding-left: 0"> Media Partners</h3> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4284.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> The Medicine Maker</h3> <div class="subtitle"> Official Media Partner</div> <a href="https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo" target="_blank" class="link" align="right"> https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo</a> <br /> <br /> <div class="textbody"> The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.pharmaphorum.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/2411.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> pharmaphorum</h3> <div class="subtitle"> Official Media Partner</div> <a href="http://www.pharmaphorum.com" target="_blank" class="link" align="right"> http://www.pharmaphorum.com</a> <br /> <br /> <div class="textbody"> pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://ondrugdelivery.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/2920.jpg" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> ONdrugDelivery Magazine</h3> <div class="subtitle"> Official Media Partner</div> <a href="http://ondrugdelivery.com" target="_blank" class="link" align="right"> http://ondrugdelivery.com</a> <br /> <br /> <div class="textbody"> ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe. </div> <br /> </div> </div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 30%; display: table-cell; vertical-align: top; float: left;"> <a href="http://www.pharmajournalist.com" target="_blank"> <img src="https://www.smgconferences.com/_media/partners/4110.png" alt="sponsor image" class="img-responsive popup-image" align="left" /></a> </div> <div class="s-right-side" style="width: 70%; display: table-cell; padding-left: 10px;"> <h3 style="padding-left: 0px; margin: 0px"> Pharma Journalist </h3> <div class="subtitle"> Official Media Partner</div> <a href="http://www.pharmajournalist.com" target="_blank" class="link" align="right"> http://www.pharmajournalist.com</a> <br /> <br /> <div class="textbody"> Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers. </div> <br /> </div> </div> </div> <div id="pop-ical" class="ical-popup mfp-hide"> <h3 style="padding-left: 0px; margin: 0px"> SAVE TO</h3> <br /> <img src="/_images/newsite/cal-1.jpg" alt="Outlook Calendar" />  <a href="/pharmaceuticals/uk/conference/rna-therapeutics/event.ics" style="color: #000">OUTLOOK CALENDAR</a><br /> <img src="/_images/newsite/cal-2.jpg" alt="Google Calendar" />  <a href="http://www.google.com/calendar/event?action=TEMPLATE&text=RNA+Therapeutics+&dates=20250210T080000Z/20250211T181000Z&details=SAE+Media+Group+is+proud+to+present+the+15th+Annual+RNA+Therapeutics+Conference+on+10+-+11th+February+2025.&location=Hilton+London+Kensington%2c+London&sprop=website:www.smi-online.co.uk" style="color: #000">GOOGLE CALENDAR</a><br /> <img src="/_images/newsite/cal-3.jpg" alt="ICal Calendar" />  <a href="/pharmaceuticals/uk/conference/rna-therapeutics/event.ics" style="color: #000">ICAL CALENDAR</a><br /> <img src="/_images/newsite/cal-4.jpg" alt="Yahoo! Calendar" />  <a href="http://calendar.yahoo.com/?v=60&TYPE=18&TITLE=RNA+Therapeutics+&ST=20250210T080000Z&ET=20250211T181000Z&in_loc=Hilton+London+Kensington%2c+London&DESC=SAE+Media+Group+is+proud+to+present+the+15th+Annual+RNA+Therapeutics+Conference+on+10+-+11th+February+2025." style="color: #000">YAHOO! CALENDAR</a><br /> </div> <div id="pop-venue" class="white-popup mfp-hide"> <h3 style="padding-left: 0px; margin: 0px"> Hilton London Kensington</h3> 179-199 Holland Park Avenue<br/> London W11 4UL<br/> United Kingdom<br/> <br /> <div class="clearfix"> <div class="s-left-side" style="width: 50%; display: table-cell; vertical-align: top; float: left;"> <img src="/documentPortal/venueImages/319.jpg?width=350" alt="Hilton London Kensington" class="img-responsive" /> </div> <div class="s-right-side" style="width: 50%; display: table-cell; float: left; text-align: right"> <iframe class="iframe-map" style="height: 350px; width: 100%; padding-left: 10px; border: 0" src="https://www.google.com/maps/d/u/0/embed?mid=zDxkJou5X4vI.k2pc1IMkZJhg" frameborder="0"></iframe> </div> </div> <br /> <p>At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.</p> <div style="margin: 0cm"> <div style="margin: 0cm"> </div> <div style="margin: 0cm">Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”</div> </div> <div style="margin-top:20px;"> <a href="/documentPortal/hotelBookingForms/6065.pdf" class="log_btn" target="_blank">HOTEL BOOKING FORM</a> </div> </div> <div id="pop-speaker-single" class="white-popup mfp-hide"> <br /> <div class="clearfix"> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0px; margin: 0px"> Title</h3> <span class="subtitle">SubTitle</span> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <img src="" alt="speaker image" class="img-responsive popup-image" align="right" /> </div> </div> <br /> <div class="textbody"> Content </div> </div> <div id="pop-media-single" class="white-popup mfp-hide"> <br /> <div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0; margin: 0"> </h3> <div class="subtitle"> </div> <a href="" target="_blank" class="link"> </a> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <a href="" target="_blank" class="imagelink"> <img src="" alt="sponsor image" class="img-responsive popup-image" align="right" /></a> </div> </div> <br /> <div class="textbody"> </div> </div> </div> <div id="pop-download" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> </div> <div id="pop-download-presentation" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> <a href="#pop-login" class="open-popup-link log_btn login_link">Login</a><br /> </div> <div id="pop-video" class="mfp-hide white-popup"> <h3 class="title" style="padding-left: 0px; margin: 0px">Title</h3><br /> <div class="desc">Description</div><br /> <div class="video"><iframe class="if" src="" width="640" height="564" frameborder="0" allow="autoplay; fullscreen" allowfullscreen></iframe></div><br /> <a href="javascript:void(0)" class="link log_btn">Download</a> <a href="#pop-login" class="open-popup-link log_btn login_link">Login</a><br /> </div> <div class="container-fluid darkgrey"> <footer class="container"> <div class="contact-details"> <ul class="contact"> <li><a href="#pop-contact" class="open-popup-link">+44 (0)20 7827 6000</a></li> <li><a href="#pop-contact" class="open-popup-link">events@saemediagroup.com</a></li> </ul> <a href="#pop-cpd" class="open-popup-link"><img src="/_images/newsite/cpd.png" alt="" /></a> </div> <div class="participate"> <a href="#pop-speak" class="open-popup-link">Speak</a> <a href="#pop-sponsor" class="open-popup-link">Sponsor</a> <a href="#pop-attend" class="open-popup-link">Attend</a> <a href="/about-us/help">Help</a> <span> <a href="#pop-register" class="open-popup-link">Sign up</a>/<a href="#pop-login" class="open-popup-link">Login</a> </span> </div> <div> <ul class="nav navbar-nav"> <li><a href="/Default.aspx">Home</a></li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl00_sLnk" href="/defence/">Defence & Security</a> </li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl01_sLnk" href="/utility/">Utilities</a> </li> <li> <a id="ctl00_footer_navbar_footer_list_rSector_ctl02_sLnk" class="sectorselected" href="/pharmaceuticals/">Pharmaceuticals</a> </li>  <li> <a href="https://www.saemediagroup.com" target="_blank">Digital & Print Media</a> </li> </ul> </div> <div class="follow"> <p>follow us</p> <a href="http://www.linkedin.com/company/407332" class="linkedin" target="_blank"></a> <a href="https://twitter.com/SAEMGPharma" class="twitter" target="_blank"></a> </div> </footer> <hr /> <p class="copyright"> copyright © 2024 SAE Media Group</p> </div> <div id="cookie-use" class="cookie-use"> <div id="logo" class="cookie_img"> <a href="/"> <img alt="Home" src="/_images/newsite/logo.png" class="img-responsive" /></a> </div> <div class="cookie_content"> <h1> Cookie Policy</h1> <p> From May 2011 a new privacy law came into effect across the EU. The law requires that websites ask visitors for consent to use most web cookies. We use cookies to ensure you get the best experience on our website –Tick here to accept cookie use <input type="checkbox" id="cbAcceptCookieUse" /><br /> Details of our cookie use may be found <a href="/cookies">here</a>. </p> </div> </div> <script type="text/javascript"> //<![CDATA[ (function() {var fn = function() {$get("ctl00_ToolkitScriptManager1_HiddenField").value = '';Sys.Application.remove_init(fn);};Sys.Application.add_init(fn);})();//]]> </script> </form> <div id="pop-cpd" class="white-popup mfp-hide"> <img src="/_images/newsite/cpd-large.jpg"><br> <h3> WHAT IS CPD?</h3> <p> CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is: </p> <p> <i>‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’</i> </p> <p> CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities. </p> <p> Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld. </p> <p> CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading. </p> <h3> CPD AND PROFESSIONAL INSTITUTES</h3> <p> There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD. </p> <p> For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained. </p> <p> CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities. </p> <h3> TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)</h3> <p> Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based. </p> <p> <b>‘Input’</b> based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning. </p> <p> <b>‘Output’</b> based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning. </p> <p> The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently. </p> <p> As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements. </p> <h3> GLOBAL CPD</h3> <p> Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace. </p> <h3>CPD Certificates</h3> <p> We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email <a href="mailto:events@saemediagroup.com">events@saemediagroup.com</a> </p> </div> <div id="pop-news" class="white-popup mfp-hide"> <h3 class="news-evttitle" style="padding-left: 0px"> Event Title</h3> <h3 class="news-headline" style="padding-left: 0px"> Headline</h3> <div class="news-text"> Text </div> <a href="javascript:void(0)" class="news-evtlink log_btn" >Read More</a> </div> <div id="pop-speak" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>I would like to speak at an event</h3> <div class="register_sec"> <form id="speak_form" action="" method="post"> <div class="ctrl-grp"> <label class="title"> Which conference are you interested in speaking at?</label> <select id="speak_conf" name="speak_conf" class="register-select conf_group"> <option value="">Select ...</option><option value="6030">Counter UAS Technology USA </option><option value="6043">Energy From Waste</option><option value="6029">Military Airlift and Air-to-Air Refuelling</option><option value="6057">Pre-Filled Syringes and Injectable Drug Devices </option><option value="6061">Maritime Reconnaissance and Surveillance Technology</option><option value="6060">Mobile Deployable Communications</option><option value="6063">UAV Technology USA</option><option value="6064">Counter UAS Homeland Security USA</option><option value="6065">RNA Therapeutics </option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option> </select> </div> <div class="ctrl-grp"> <label class="title">Not listed above?</label> <input type="text" id="speak_notlisted" name="speak_notlisted" value="" class="form-control conf_group" spellcheck="false" /> </div> <div class="ctrl-grp"> <label class="title"> How can we help?</label> <textarea id="speak_help" name="speak_help" class="form-control"></textarea> </div> <div class="indent"> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="speak_org" name="speak_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Website</label> <input type="text" id="speak_website" name="speak_website" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Title</label>  <select id="speak_title" name="speak_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="speak_title_other" name="speak_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#speak_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#speak_title_other').prop('disabled', false); $('#speak_title_other').css({ 'background-color': '#fff' }); $('#speak_title_other').parent().slideDown(); } else { $('#speak_title_other').val(''); $('#speak_title_other').prop('disabled', true); $('#speak_title_other').css({ 'background-color': '#ccc' }); $('#speak_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="speak_firstname" name="speak_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="speak_surname" name="speak_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="speak_email" name="speak_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Phone*</label> <input type="text" id="speak_phone" name="speak_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="speak_add" name="speak_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <label class="title"> What is the topic you wish to speak about?</label> <textarea id="speak_topic" name="speak_topic" class="form-control"></textarea> </div> <div class="ctrl-grp checkbox-grp"> <div><input id="speak_returning" name="speak_returning" type="checkbox" /></div> <label for="speak_returning"> I'm a returning speaker from a previous event</label> </div> <div class="ctrl-grp"> <label class="title"> Where did you hear about SAE Media Group?</label> <input type="text" id="speak_hear" name="speak_hear" value="" class="form-control" /> </div> <input id="speak_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-attend-group" class="white-popup mfp-hide"></div> <div id="pop-attend" class="white-popup mfp-hide"> <div style="width: 100%"> <h3 id="popTitle">I would like to attend an event</h3> <h3 id="popGroupTitle">Group Booking</h3> <h4 id="popGroupSubTitle" style="padding-left:80px;">Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours</h4> <div class="register_sec"> <form id="attend_form" action="" method="post"> <div class="ctrl-grp" id="divAttendConf"> <label class="title">Which conference are you interested in attending?</label> <select id="attend_conf" name="attend_conf" class="register-select conf_group"> <option value="">Select ...</option><option value="6030">Counter UAS Technology USA </option><option value="6043">Energy From Waste</option><option value="6029">Military Airlift and Air-to-Air Refuelling</option><option value="6057">Pre-Filled Syringes and Injectable Drug Devices </option><option value="6061">Maritime Reconnaissance and Surveillance Technology</option><option value="6060">Mobile Deployable Communications</option><option value="6063">UAV Technology USA</option><option value="6064">Counter UAS Homeland Security USA</option><option value="6065">RNA Therapeutics </option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option> </select> </div>   <div class="indent"> <div class="ctrl-grp" id="divGroupSize"> <label>Group size</label> <input type="text" id="attend_groupSize" name="attend_groupSize" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="attend_org" name="attend_org" value="" class="form-control" spellcheck="false" /> </div>  <div class="ctrl-grp"> <label>Title</label>  <select id="attend_title" name="attend_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="attend_title_other" name="attend_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#attend_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#attend_title_other').prop('disabled', false); $('#attend_title_other').css({ 'background-color': '#fff' }); $('#attend_title_other').parent().slideDown(); } else { $('#attend_title_other').val(''); $('#attend_title_other').prop('disabled', true); $('#attend_title_other').css({ 'background-color': '#ccc' }); $('#attend_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="attend_firstname" name="attend_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="attend_surname" name="attend_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="attend_email" name="attend_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Phone*</label> <input type="text" id="attend_phone" name="attend_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="attend_add" name="attend_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp checkbox-grp" id="divAttendReturning"> <div><input id="attend_returning" name="attend_returning" type="checkbox" /></div> <label for="attend_returning">I'm a returning attendee from a previous event</label> </div>  <input id="attend_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-sponsor" class="white-popup mfp-hide"> <div style="width: 100%"> <h3 id="hSponsorExhibit">I would like to sponsor/exhibit at an event</h3> <div class="register_sec"> <form id="sponsor_form" action="" method="post"> <div class="ctrl-grp" id="divWhichConf"> <label class="title">Which conference are you interested in sponsoring?</label> <select id="sponsor_conf" name="sponsor_conf" class="conf_group"> <option value="">Select ...</option><option value="6030">Counter UAS Technology USA </option><option value="6043">Energy From Waste</option><option value="6029">Military Airlift and Air-to-Air Refuelling</option><option value="6057">Pre-Filled Syringes and Injectable Drug Devices </option><option value="6061">Maritime Reconnaissance and Surveillance Technology</option><option value="6060">Mobile Deployable Communications</option><option value="6063">UAV Technology USA</option><option value="6064">Counter UAS Homeland Security USA</option><option value="6065">RNA Therapeutics </option><option value="6073">AI in Drug Discovery</option><option value="6075">Future Soldier Technology</option><option value="6077">Military Robotics & Autonomous Systems</option><option value="6080">Counter UAS Technology Europe</option><option value="6103">Loitering Munitions USA</option><option value="6081">Smart Water Systems</option><option value="6084">Future Armoured Vehicles Situational Awareness</option><option value="6083">Military Space Situational Awareness </option><option value="6068">Pre-Filled Syringes and Injectable Drug Devices East Coast</option><option value="6093">Future Armoured Vehicles Central and Eastern Europe</option><option value="6094">Helicopter Technology Central and Eastern Europe</option><option value="6067">Pre-Filled Syringes and Injectable Drug Devices West Coast</option><option value="6097">Future Soldier Technology USA</option><option value="6099">MILSATCOM USA</option><option value="6092">Injectable Drug Delivery</option><option value="6106">Counter UAS Middle East & Africa</option><option value="6101">Military Robotics and Autonomous Systems USA</option><option value="6112">Unmanned Maritime Systems Technology USA</option><option value="6114">The Space Logistics Conference</option><option value="6115">Defence Exports</option><option value="6108">Counter UAS Homeland Security Europe</option><option value="6118">UAV Technology</option><option value="6133">Defence Aviation Safety</option><option value="6105">Counter UAS Commercial Shipping</option><option value="6121">Airborne ISR</option><option value="6125">Global MilSatCom 2025</option><option value="6130">Air and Missile Defence Technology </option><option value="6132">Loitering Munitions</option><option value="6128">Future Armoured Vehicles Survivability</option> </select> </div> <div class="ctrl-grp" id="divNotListed"> <label class="title">Not listed above?</label> <input id="sponsor_notlisted" name="sponsor_notlisted" type="text" value="" class="form-control conf_group" spellcheck="false" /> </div> <div class="ctrl-grp hidden"> <label class="title"> What type of sponsorship are you interested in?</label> <ul class="checkbox-list"> <li> <input id="sponsor_lead" name="sponsor_lead" type="checkbox" /> <label for="sponsor_lead">Lead Sponsor</label> </li> <li> <input id="sponsor_speaking" name="sponsor_speaking" type="checkbox" /> <label for="sponsor_speaking">Speaking</label> </li> <li> <input id="sponsor_exhibit" name="sponsor_exhibit" type="checkbox" /> <label for="sponsor_exhibit">Exhibit</label> </li> <li> <input id="sponsor_networking" name="sponsor_networking" type="checkbox" /> <label for="sponsor_networking">Networking Reception Sponsor</label> </li> <li> <input id="sponsor_coffee" name="sponsor_coffee" type="checkbox" /> <label for="sponsor_coffee">Coffee/Tea Break Sponsor</label> </li> <li> <input id="sponsor_lunch" name="sponsor_lunch" type="checkbox" /> <label for="sponsor_lunch">Lunch Sponsor</label> </li> <li> <input id="sponsor_branding" name="sponsor_branding" type="checkbox" /> <label for="sponsor_branding">Branding Package</label> </li> <li> <input id="sponsor_lanyards" name="sponsor_lanyards" type="checkbox" /> <label for="sponsor_lanyards">Lanyards Sponsor</label> </li> </ul> </div> <div class="indent"> <div class="ctrl-grp"> <label>Organisation*</label> <input type="text" id="sponsor_org" name="sponsor_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp hidden"> <label>Website</label> <input type="text" id="sponsor_website" name="sponsor_website" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Job Title*</label> <input type="text" id="sponsor_jobtitle" name="sponsor_jobtitle" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Title</label>  <select id="sponsorVar_title" name="sponsorVar_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="sponsor_title_other" name="sponsor_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#sponsorVar_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#sponsor_title_other').prop('disabled', false); $('#sponsor_title_other').css({ 'background-color': '#fff' }); $('#sponsor_title_other').parent().slideDown(); } else { $('#sponsor_title_other').val(''); $('#sponsor_title_other').prop('disabled', true); $('#sponsor_title_other').css({ 'background-color': '#ccc' }); $('#sponsor_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label>First Name*</label> <input type="text" id="sponsor_firstname" name="sponsor_firstname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Surname*</label> <input type="text" id="sponsor_surname" name="sponsor_surname" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Email*</label> <input type="text" id="sponsor_email" name="sponsor_email" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label>Phone*</label> <input type="text" id="sponsor_phone" name="sponsor_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp ffh"> <label>Address*</label> <input type="text" id="sponsor_add" name="sponsor_add" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp hidden"> <label class="title">What are your sponsorship goals?</label> <textarea id="sponsor_goals" name="sponsor_goals" class="form-control"></textarea> </div> <div class="ctrl-grp checkbox-grp hidden"> <div><input id="sponsor_returning" name="sponsor_returning" type="checkbox" value="true"></div> <label for="sponsor_returning">I'm a returning sponsor from a previous event</label> </div> <div class="ctrl-grp hidden"> <label class="title">Where did you hear about SAE Media Group?</label> <input id="sponsor_hear" name="sponsor_hear" type="text" value="" class="form-control" /> </div> <input id="sponsor_submit" type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-login" class="white-popup mfp-hide"> <div style="width: 100%"> <h3> SIGN UP OR LOGIN</h3> <div class="register_sec"> <div class="sign_linkd hidden"> <a href="javascript:void(0)">SIGN UP/LOG IN with linked in</a> </div> <form id="login_form" action="" method="post"> <input id="login_reload" type="hidden" value="" /> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="login_email" name="login_email" type="text" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> PASSWORD*</label> <input id="login_password" name="login_password" type="password" value="" class="form-control" autocomplete="off" /> </div> </div> <div class="ctrl-grp checkbox-grp"> <input id="login_rememberme" name="login_rememberme" type="checkbox" /> <label for="login_rememberme"> Keep me signed in</label> </div> <div> <a href="#pop-register" id="sign_btn_link" class="open-popup-link sign_btn">Sign up</a> <input id="login_button" type="submit" value="Log In" class="log_btn" /> </div> <div style="margin-top: 20px;"> <a href="#pop-forgot" class="open-popup-link">Forgotten Password?</a> </div> </form> <div id="login_failed" style="display: none"> <p> Sorry, the login details you entered were not found. Please try again. Alternatively you may register a new account <a href="#pop-register" class="open-popup-link">here</a>. </p> <p> Accounts are locked after <span id="ctl00_popupLogin_maxAttempts">5</span> failed attempts.</p> </div> </div> </div> </div> <div id="pop-register" class="white-popup mfp-hide"> <div style="width: 100%"> <center> <img src="/_images/newsite/logo.png" style="text-align: center" /></center> <div class="register_sec"> <form id="register_form" action="" method="post"> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="register_email" name="register_email" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> PASSWORD*</label> <input id="register_password" name="register_password" type="password" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> CONFIRM*</label> <input id="register_confirm" name="register_confirm" type="password" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label>TITLE*</label>  <select id="register_title" name="register_title" class="form-control title_group" style="" spellcheck="false"> <option>Mr</option> <option>Mrs</option> <option>Miss</option> <option>Ms</option> <option>Dr</option> <option selected="selected">Select ...</option> <option>1st Lieutenant</option> <option>1st Sergeant</option> <option>2nd Lieutenant</option> <option>Admiral</option> <option>Admiral Sir</option> <option>Air Chief Marshall</option> <option>Air Commodore</option> <option>Air Marshal</option> <option>Air Vice Marshal</option> <option>Ambassador</option> <option>Archbishop</option> <option>Assistant Chief Constable</option> <option>Assistant Commissioner</option> <option>Assistant Director</option> <option>Assistant Professor</option> <option>Associate Professor</option> <option>Attorney</option> <option>Baron</option> <option>Baroness</option> <option>Bishop</option> <option>blank</option> <option>Brigadier</option> <option>Brigadier General</option> <option>Brigadier General (Ret’d)</option> <option>Brother</option> <option>Bsc</option> <option>Captain</option> <option>Chairman</option> <option>Chef de service administratif</option> <option>Chef D'escadron</option> <option>Chief</option> <option>Chief Constable</option> <option>Chief Inspector</option> <option>Chief Mast Sergeant</option> <option>Chief Petty Officer</option> <option>Chief Sergeant</option> <option>Chief Superintendent</option> <option>Colonel</option> <option>Colonel (Ret’d)</option> <option>Commandant</option> <option>Commander</option> <option>Commander Captain</option> <option>Commander General</option> <option>Commissaire Capitaine</option> <option>Commissaire Colonel</option> <option>Commissaire commandant</option> <option>Commissaire en chef</option> <option>Commissaire General</option> <option>Commissaire General de brigade</option> <option>Commissaire general de division</option> <option>Commissaire lieutenant</option> <option>Commissaire Lieutenant Colonel</option> <option>Commissaire principal</option> <option>Commissioner</option> <option>Commodore</option> <option>Commodore (Ret’d)</option> <option>Congressman</option> <option>Contre-Amiral</option> <option>Controleur des Armees</option> <option>Controleur general des armees</option> <option>Corporal</option> <option>Councillor</option> <option>Dame</option> <option>Datuk</option> <option>Deputy</option> <option>Deputy Assistant Commissioner</option> <option>Deputy Chief Constable</option> <option>Deputy Commissioner</option> <option>Deputy Director General</option> <option>Detective</option> <option>Detective Chief Inspector</option> <option>Detective Constable</option> <option>Detective Inspector</option> <option>Detective Sargeant</option> <option>Detective Superintendent</option> <option>Director</option> <option>Doctor</option> <option>Earl</option> <option>Esq</option> <option>Father</option> <option>Federal Agent</option> <option>Flight Lieutenant</option> <option>Flight Sergeant</option> <option>Frau</option> <option>Frau Dr</option> <option>General</option> <option>General (Ret'd)</option> <option>General Manager</option> <option>General Sir</option> <option>Governor</option> <option>Grand Duke</option> <option>Group Captain</option> <option>Herr</option> <option>Herr Dr</option> <option>His Excellency</option> <option>His Grace Most Rev</option> <option>His Highness</option> <option>His Honour</option> <option>His Majesty King</option> <option>His Royal Highness</option> <option>His Royal Highness Prince</option> <option>Honourable</option> <option>Honourable Dr</option> <option>Honourable Judge</option> <option>Honourable Mr Justice</option> <option>Ing</option> <option>Ingenieur des ETA</option> <option>Ingenieur d'etudes et de fabrications</option> <option>Ingenieur divissionaire des TPE</option> <option>Ingenieur en chef 1c des ETTM</option> <option>Ingenieur en chef de l'armement</option> <option>Ingenieur en chef de l'armentent</option> <option>Ingenieur en chef des ETA</option> <option>Ingenieur en chef des P et C</option> <option>Ingenieur general 2c de l'armemnt</option> <option>Ingenieur general de l'armement</option> <option>Ingenieur General hc de l'armement</option> <option>Ingenieur principal de l'armement</option> <option>Ingenieur principal des ETA</option> <option>Inspecteur principal des impots</option> <option>Inspector</option> <option>Inspector General</option> <option>Judge</option> <option>King</option> <option>Lady</option> <option>Lieutenant</option> <option>Lieutenant Commander</option> <option>Lieutenant Colonel</option> <option>Lieutenant Colonel (Ret'd)</option> <option>Lieutenant Commander</option> <option>Lieutenant General</option> <option>Lieutenant General Sir</option> <option>Lord</option> <option>Ma</option> <option>Madame</option> <option>Magistrat Lieutenant Colonel</option> <option>Major</option> <option>Major (Ret'd)</option> <option>Major Brigadier</option> <option>Major General</option> <option>Major General (ret'd)</option> <option>Major Sargeant</option> <option>Managing Director</option> <option>Master Sergeant</option> <option>Minister</option> <option>Monsieur</option> <option>Monsignor</option> <option>Most Reverend</option> <option>Most Reverend Archbishop</option> <option>Most Reverend Bishop</option> <option>Most Reverend Dr</option> <option>MP</option> <option>Mr.</option> <option>Ms.</option> <option>Msc</option> <option>myt</option> <option>Ph.D</option> <option>Police Constable</option> <option>Police Director</option> <option>President</option> <option>President & Chief Executive Officer</option> <option>Prince</option> <option>Prof</option> <option>Professor</option> <option>Professor Dame</option> <option>Professor Dr</option> <option>Rear Admiral</option> <option>Reverend</option> <option>Reverend Dr</option> <option>Reverend Professor</option> <option>Right Admiral</option> <option>Right Honourable</option> <option>Right Rev</option> <option>Rt Hon</option> <option>Rt Hon Dame</option> <option>Rt Hon Lord</option> <option>Rt Hon Lord Justice</option> <option>Rt Hon Sir</option> <option>Rt Honourable</option> <option>Rt Rev</option> <option>Rt Rev Dr</option> <option>Rt Rev Lord</option> <option>Rt Rev Mgr</option> <option>Rt Rev Monsignor</option> <option>Rt. Hon</option> <option>Senator</option> <option>Senior General</option> <option>Sergeant</option> <option>Sergeant Major</option> <option>Sheikh</option> <option>Sir</option> <option>Sister</option> <option>Sous-lieutenant</option> <option>Squadron Leader</option> <option>Squadron Leader (Ret'd)</option> <option>Staff Brigadier</option> <option>Staff Sergeant</option> <option>Sultan</option> <option>Superintendent</option> <option>Surgeon Commodore</option> <option>Surgeon Rear Admiral</option> <option>Surgeon Vice Admiral</option> <option>The Honourable</option> <option>The Honourable Dr</option> <option>The Honourable Lord</option> <option>The Honourable Miss</option> <option>The Honourable Mr</option> <option>The Honourable Mr Justice</option> <option>The Most Reverend</option> <option>The Right Honourable</option> <option>The Right Honourable Baroness</option> <option>The Right Honourable Lord</option> <option>The Right Honourable Sir</option> <option>The Right Reverend</option> <option>Very Reverend</option> <option>Very Reverend Dr</option> <option>Vice Admiral</option> <option>Vice Admiral d'escadre</option> <option>Vice Admiral Sir</option> <option>Vice Amiral d'escadre</option> <option>Vice Chairman</option> <option>Vice President</option> <option>Viscount</option> <option>Warrant Officer</option> <option>Wing Commander</option> <option>Other</option> </select> <div style="display:none;"> <input type="text" id="register_title_other" name="register_title_other" value="" class="form-control title_group" style="margin:10px 0 0 178px; background-color: #ccc;" spellcheck="false" disabled="disabled" /> </div> <script> $(document).ready(function () { $("#register_title").change(function () { if ($("option:selected", this).text() == 'Other') { $('#register_title_other').prop('disabled', false); $('#register_title_other').css({ 'background-color': '#fff' }); $('#register_title_other').parent().slideDown(); } else { $('#register_title_other').val(''); $('#register_title_other').prop('disabled', true); $('#register_title_other').css({ 'background-color': '#ccc' }); $('#register_title_other').parent().slideUp(); } }); }); </script> </div> <div class="ctrl-grp"> <label> FIRST NAME*</label> <input id="register_firstname" name="register_firstname" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> SURNAME*</label> <input id="register_surname" name="register_surname" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> COUNTRY*</label> <select id="register_country" name="register_country" class="register-select"> <option value="">Select ...</option><option value="222">United Kingdom</option><option value="223">USA</option><option value="85">Germany</option><option value="78">France</option><option value="108">Italy</option><option value="102">India</option><option value="154">Netherlands</option><option value="205">Switzerland</option><option value="26">Belgium</option><option value="">------------------------------</option><option value="1">Afghanistan</option><option value="2">Albania</option><option value="3">Algeria</option><option value="4">American Samoa</option><option value="5">Andorra</option><option value="6">Angola</option><option value="7">Anguilla</option><option value="8">Antarctica-Casey</option><option value="9">Antarctica-Scott</option><option value="10">Antigua and Barbuda</option><option value="11">Argentina</option><option value="12">Armenia</option><option value="13">Aruba</option><option value="14">Ascension Islands</option><option value="15">Ashmore & Cartier Islands</option><option value="16">Atlantic East</option><option value="17">Atlantic West</option><option value="18">Australia</option><option value="19">Austria</option><option value="20">Azerbaijan</option><option value="21">Bahamas</option><option value="22">Bahrain</option><option value="23">Bangladesh</option><option value="24">Barbados</option><option value="25">Belarus</option><option value="27">Belize</option><option value="28">Benin</option><option value="29">Bermuda</option><option value="30">Bhutan</option><option value="31">Bolivia</option><option value="32">Bosnia and Herzegovina</option><option value="33">Botswana</option><option value="34">Brazil</option><option value="36">Brunei Darussalam</option><option value="37">Bulgaria</option><option value="38">Burkina Faso</option><option value="39">Burma</option><option value="40">Burundi</option><option value="41">Cambodia</option><option value="42">Cameroon</option><option value="43">Canada</option><option value="240">Canary Islands</option><option value="44">Cape Verde</option><option value="45">Cayman Islands</option><option value="46">Central African Republic</option><option value="47">Chad</option><option value="48">Chile</option><option value="49">China</option><option value="50">Christmas Island</option><option value="51">Clipperton Island</option><option value="52">Cocos (Keeling) Islands</option><option value="53">Colombia</option><option value="54">Comoros</option><option value="55">Congo</option><option value="56">Cook Islands</option><option value="57">Costa Rica</option><option value="58">Croatia</option><option value="59">Cuba</option><option value="60">Cyprus</option><option value="61">Czech Republic</option><option value="62">Denmark</option><option value="63">Djibouti</option><option value="64">Dominica</option><option value="65">Dominican Republic</option><option value="241">Easter Island</option><option value="67">Ecuador</option><option value="68">Egypt</option><option value="69">El Salvador</option><option value="70">Equatorial Guinea</option><option value="71">Eritrea</option><option value="72">Estonia</option><option value="73">Ethiopia</option><option value="254">Europe</option><option value="74">Falkland Islands</option><option value="75">Faroe Islands</option><option value="76">Fiji</option><option value="77">Finland</option><option value="79">French Guiana</option><option value="80">French Polynesia</option><option value="81">Gabon</option><option value="242">Galapagos Islands</option><option value="82">Gambia</option><option value="83">Gaza Strip</option><option value="84">Georgia</option><option value="86">Ghana</option><option value="87">Gibraltar</option><option value="88">Greece</option><option value="89">Greenland</option><option value="90">Grenada</option><option value="91">Guadeloupe</option><option value="92">Guam</option><option value="93">Guatemala</option><option value="94">Guinea</option><option value="95">Guinea-Bissau</option><option value="96">Guyana</option><option value="97">Haiti</option><option value="252">Hawaii</option><option value="98">Honduras</option><option value="99">Hong Kong</option><option value="100">Hungary</option><option value="101">Iceland</option><option value="103">Indonesia</option><option value="104">Iran, Islamic Republic of</option><option value="105">Iraq</option><option value="106">Ireland</option><option value="107">Israel</option><option value="110">Ivory Coast</option><option value="111">Jamaica</option><option value="112">Japan</option><option value="113">Jordan</option><option value="114">Kazakhstan</option><option value="115">Kenya</option><option value="116">Kiribati</option><option value="119">Kuwait</option><option value="120">Kyrgyzstan</option><option value="121">Laos</option><option value="122">Latvia</option><option value="123">Lebanon</option><option value="124">Lesotho</option><option value="125">Liberia</option><option value="126">Libya</option><option value="127">Liechtenstein</option><option value="128">Lithuania</option><option value="129">Luxembourg</option><option value="130">Macau</option><option value="131">Macedonia</option><option value="132">Madagascar</option><option value="133">Malawi</option><option value="134">Malaysia</option><option value="135">Maldives</option><option value="136">Mali</option><option value="137">Malta</option><option value="163">Marianas Islands</option><option value="138">Marshall Islands</option><option value="139">Martinique</option><option value="140">Mauritania</option><option value="141">Mauritius</option><option value="142">Mayotte Islands</option><option value="143">Mexico</option><option value="144">Micronesia</option><option value="145">Moldova</option><option value="146">Monaco</option><option value="147">Mongolia</option><option value="244">Montenegro</option><option value="148">Montserrat</option><option value="149">Morocco</option><option value="150">Mozambique</option><option value="245">Myanmar</option><option value="151">Namibia</option><option value="152">Nauru</option><option value="153">Nepal</option><option value="155">Netherlands Antilles</option><option value="156">New Caledonia</option><option value="157">New Zealand</option><option value="158">Nicaragua</option><option value="159">Niger</option><option value="160">Nigeria</option><option value="161">Niue</option><option value="255">None</option><option value="162">Norfolk Island</option><option value="117">North Korea</option><option value="164">Norway</option><option value="165">Oman</option><option value="166">Pakistan</option><option value="167">Palau</option><option value="251">Palestine</option><option value="168">Panama</option><option value="169">Papua New Guinea</option><option value="170">Paraguay</option><option value="171">Peru</option><option value="172">Philippines</option><option value="173">Poland</option><option value="174">Portugal</option><option value="175">Puerto Rico</option><option value="176">Qatar</option><option value="177">Réunion</option><option value="178">Romania</option><option value="179">Russia</option><option value="180">Rwanda</option><option value="181">Saint Helena</option><option value="182">Saint Kitts and Nevis</option><option value="183">Saint Lucia</option><option value="184">Saint Vincent/Grenadines</option><option value="185">Samoa</option><option value="186">San Marino</option><option value="187">Sao Tome</option><option value="188">Saudi Arabia</option><option value="253">Scotland</option><option value="189">Senegal</option><option value="246">Serbia</option><option value="190">Seychelles</option><option value="191">Sierra Leone</option><option value="192">Singapore</option><option value="193">Slovakia</option><option value="194">Slovenia</option><option value="195">Solomon Islands</option><option value="196">Somalia</option><option value="197">Somoa Western</option><option value="198">South Africa</option><option value="118">South Korea</option><option value="199">Spain</option><option value="200">Sri Lanka</option><option value="201">Sudan</option><option value="202">Suriname</option><option value="203">Swaziland</option><option value="204">Sweden</option><option value="206">Syria</option><option value="247">Tahiti</option><option value="207">Taiwan</option><option value="208">Tajikistan</option><option value="209">Tanzania</option><option value="248">Tatarstan</option><option value="256">TBC</option><option value="210">Thailand</option><option value="211">Togo</option><option value="212">Tonga</option><option value="213">Trinidad and Tobago</option><option value="214">Tunisia</option><option value="215">Turkey</option><option value="216">Turkmenistan</option><option value="217">Turks and Caicos Islands</option><option value="218">Tuvalu</option><option value="219">Uganda</option><option value="220">Ukraine</option><option value="221">United Arab Emirates</option><option value="224">Uruguay</option><option value="225">Uzbekistan</option><option value="249">Vanatu</option><option value="226">Vanuatu</option><option value="227">Vatican City (Holy See)</option><option value="228">Venezuela</option><option value="229">Vietnam</option><option value="35">Virgin Islands, British</option><option value="230">Virgin Islands, U.S.</option><option value="231">Wallis And Futuna</option><option value="232">West Bank</option><option value="250">West Indies</option><option value="233">Western Sahara</option><option value="234">Yemen</option><option value="235">Yugoslavia</option><option value="236">Zaire</option><option value="237">Zambia</option><option value="238">Zimbabwe</option> </select> </div> <div class="ctrl-grp"> <label> ORGANISATION*</label> <input id="register_org" name="register_org" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> JOB TITLE*</label> <input id="register_jobtitle" name="register_jobtitle" type="text" value="" class="form-control" /> </div> <div class="ctrl-grp"> <label> PHONE*</label> <input id="register_phone" name="register_phone" type="text" value="" class="form-control" /> </div> </div> <div class="ctrl-grp checkbox-grp"> <div><input id="register_subscribe" name="register_subscribe" type="checkbox" /></div> <label for="register_subscribe"> I would like to receive information about other SAE Media Group products and services</label> </div> <div class="ctrl-grp checkbox-grp"> <div> <input id="register_rememberme" name="register_rememberme" type="checkbox" /></div> <label for="register_rememberme"> Keep me logged in</label> </div> <div class="ctrl-grp checkbox-grp"> <div> <input id="register_terms" name="register_terms" type="checkbox" /></div> <label for="register_terms"> * I have read and understood the full Terms of Use (please click <a href="/privacy-legals/terms-of-use" target="_blank">here</a> to see full Terms of Use - please note these will open in a new window). These Terms and Conditions are governed by English law.</label> </div> <input id="register_signup" type="submit" value="Sign up" class="log_btn" /> </form> <label id="register_error" class="error" style="display: none"> </label> </div> </div> </div> <div id="pop-contact" class="white-popup mfp-hide"> <div style="col-md-6"> <h3> Contact SAE Media Group</h3> <div class="register_sec"> <span style="color: #08478c">UK Office</span><br /> Opening Hours: 9.00 - 17.30 (local time)<br /> SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom<br /> Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001<br /> Website: <a href="https://www.smgconferences.com/" style="color: #08478c">http://www.smgconferences.com</a> Email: <a href="mailto:events@saemediagroup.com" style="color: #08478c">events@saemediagroup.com</a><br /> Registered in England - SMi Group Ltd trading as SAE Media Group<br /> <br /> <form id="contact_form" action="" method="post"> <div class="ctrl-grp"> <label class="title"> Nature of your enquiry</label><br /> <select id="contact_enquirytype" name="contact_enquirytype" class="register-select conf_group" style="width: 88%;"> <option value="0">I have an enquiry that is not listed below</option><option value="1">I am an existing delegate on a Conference/Workshop</option><option value="2">I have a general Conference/Executive Briefing query</option><option value="3">I am interested in attending an SAE Media Group Conference as a delegate</option><option value="4">I am interested in attending an SAE Media Group Workshop/Executive Briefing as a delegate</option><option value="5">I am interested in attending an SAE Media Group Masterclass as a delegate</option><option value="6">I am interested in speaking at an SAE Media Group event</option><option value="7">I am interested in sponsoring/exhibiting at an SAE Media Group event</option><option value="8">I am interested in marketing opportunities with SAE Media Group</option><option value="9">I am interested in employment opportunities SAE Media Group</option><option value="10">I would like to suggest a Conference topic</option><option value="11">I would like to suggest a Workshop/Executive Briefing topic</option><option value="12">I would like to suggest a Masterclass topic</option><option value="13">I have a technical query regarding this web site</option><option value="15">SAE Media Group Event Communities Related</option><option value="17">Sponsor Webinars</option><option value="14">Other</option> </select> </div> <div class="indent"> <div class="ctrl-grp"> <label> Name*</label> <input type="text" id="contact_name" name="contact_name" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Job Title*</label> <input type="text" id="contact_jobtitle" name="contact_jobtitle" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Organisation*</label> <input type="text" id="contact_org" name="contact_org" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Phone*</label> <input type="text" id="contact_phone" name="contact_phone" value="" class="form-control" spellcheck="false" /> </div> <div class="ctrl-grp"> <label> Email*</label> <input type="text" id="contact_email" name="contact_email" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <label class="title"> Enquiry*</label> <textarea class="form-control" id="contact_enquiry" name="contact_enquiry"></textarea> </div> <input type="submit" value="SUBMIT DETAILS" class="log_btn" /> </form> </div> </div> </div> <div id="pop-sponsor-single" class="white-popup mfp-hide"> <br /> <div> <div class="clearfix"> <br /> <div class="s-left-side" style="width: 75%; display: table-cell; vertical-align: top; float: left;"> <h3 class="title" style="padding-left: 0; margin: 0"> </h3> <div class="subtitle"> </div> <a href="" target="_blank" class="link"> </a> </div> <div class="s-right-side" style="width: 25%; display: table-cell; float: left;"> <a href="" target="_blank" class="imagelink"> <img src="" alt="sponsor image" class="img-responsive popup-image" align="right" /></a> </div> </div> <br /> <div class="textbody"> </div> </div> </div> <div id="pop-forgot" class="white-popup mfp-hide"> <div style="width: 100%"> <h3> Forgotten Password</h3> <div class="register_sec"> <form id="forgot_form" action="" method="post"> <span>Please enter the email address you registered with. We will email you a new password.</span> <div class="indent"> <div class="ctrl-grp"> <label> EMAIL*</label> <input id="login_email" name="login_email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <input id="forgot_button" type="submit" value="Reset Password" class="log_btn" /> </form> <div id="reset_successful" style="display:none;"> <div>You have been sent an email with your new password. When you have recieved this email please continue to logon. Thank you.</div> <a href="#pop-login" class="open-popup-link log_btn">Continue</a> </div> <div id="reset_failed" style="display:none;"> <div>Sorry, we could not reset your password. Have you entered the correct email address?</div> </div> </div> </div> </div> <div id="pop-GDPRConsent" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>Thank you for visiting our event</h3> <div class="register_sec"> <form id="GDPRConsent_form" action="" method="post"> <input id="GDPRConsent_eventid" name="GDPRConsent_eventid" type="hidden" value="" /> <div class="ctrl-grp"> <h4>If you would like to receive further information about our events, please fill out the information below.</h4> </div> <div class="ctrl-grp"> <div style="float: left;margin-top:10px;"> <label>I am happy to receive information about SAE Media Group events by email:</label> </div> <div style="float: left;"> <input id="GDPRConsent_confirm" name="GDPRConsent_confirm" type="checkbox" value="" class="form-control" style="margin-left:20px;" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your email address:</label> <input id="GDPRConsent_email" name="GDPRConsent_email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your name:</label> <input id="GDPRConsent_name" name="GDPRConsent_name" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Your phone number:</label> <input id="GDPRConsent_phone" name="GDPRConsent_phone" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div> <input id="GDPRConsent_button" type="submit" value="Submit" class="log_btn" /> </div> <div style="margin-top: 20px;"> By ticking above you are consenting to receive information by email from SAE Media Group.<br /> Full details of our privacy policy can be found here <a class="open-popup-link" href="https://www.smgconferences.com/privacy-legals/privacy-policy/">https://www.smgconferences.com/privacy-legals/privacy-policy/</a>.<br /> Should you wish to update your contact preferences at any time you can contact us at <a class="open-popup-link" href="mailto:data.privacy@smgconferences.com">data.privacy@smgconferences.com</a>.<br /> Should you wish to be removed from any future mailing lists please click on the following link <a class="open-popup-link" href="http://www.smgconferences.com/opt-out">http://www.smgconferences.com/opt-out</a> </div> </form> <div id="GDPRConsent_failed" style="display: none"> <p> Sorry, the login details you entered were not found. Please try again. Alternatively you may register a new account <a href="#pop-register" class="open-popup-link">here</a>. </p> </div> </div> </div> </div> <form></form> <div id="pop-DownloadBrochure" class="white-popup mfp-hide"> <div style="width: 100%"> <h3>Fill in your details to download the brochure</h3> <div class="register_sec"> <form id="DownloadBrochure_Form" action="" method="post"> <input id="DownloadBrochure_EventID" name="DownloadBrochure_EventID" type="hidden" value="" /> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">First Name</label> <input id="DownloadBrochure_FirstName" name="DownloadBrochure_FirstName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Last Name</label> <input id="DownloadBrochure_LastName" name="DownloadBrochure_LastName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Email Address*</label> <input id="DownloadBrochure_Email" name="DownloadBrochure_Email" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Company Name*</label> <input id="DownloadBrochure_CompanyName" name="DownloadBrochure_CompanyName" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="indent"> <div class="ctrl-grp"> <label style="width:200px;">Telephone Number*</label> <input id="DownloadBrochure_TelephoneNumber" name="DownloadBrochure_TelephoneNumber" type="text" value="" class="form-control" spellcheck="false" /> </div> </div> <div class="ctrl-grp"> <div style="float: left;"> <input id="DownloadBrochure_Confirm" name="DownloadBrochure_Confirm" type="checkbox" value="" class="form-control hidden" style="margin-left:20px;" checked /> </div> </div> <div> <input id="DownloadBrochure_Button" type="submit" value="Submit" class="log_btn" /> </div> <div style="margin-top:20px; font-weight:500;"> By submitting this form you agree to our <a href="/privacy-legals/privacy-policy/">privacy policy</a> and consent to receiving communications, you may opt out at any time. </div> <div class="hidden" style="margin-top: 20px;"> By ticking above you are consenting to receive information by email from SAE Media Group.<br /> Full details of our privacy policy can be found here <a class="open-popup-link" href="https://www.smgconferences.com/privacy-legals/privacy-policy/">https://www.smgconferences.com/privacy-legals/privacy-policy/</a>.<br /> Should you wish to update your contact preferences at any time you can contact us at <a class="open-popup-link" href="mailto:data@smgconferences.com">data@smgconferences.com</a>.<br /> Should you wish to be removed from any future mailing lists please click on the following link <a class="open-popup-link" href="http://www.smgconferences.com/opt-out">http://www.smgconferences.com/opt-out</a> </div> </form> </div> </div> </div> <script type="text/javascript"> _linkedin_partner_id = "1595001"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1595001&fmt=gif" /> </noscript> <script> (function(ss,ex){ window.ldfdr=window.ldfdr||function(){(ldfdr._q=ldfdr._q||[]).push([].slice.call(arguments));}; (function(d,s){ fs=d.getElementsByTagName(s)[0]; function ce(src){ var cs=d.createElement(s); cs.src=src; cs.async=1; fs.parentNode.insertBefore(cs,fs); }; ce('https://sc.lfeeder.com/lftracker_v1_'+ss+(ex?'_'+ex:'')+'.js'); })(document,'script'); })('p1e024BvLJX4GB6d'); </script> </body> </html>

CINXE.COM

RNA Therapeutics : Pharmaceuticals : UK